View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 30, 2019	Apr. 26, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL INC
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-28
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		48,754,419
Emerging Growth Company	false
Smaller Reporting Company	false

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Total revenue	$ 604,569	$ 493,970
Costs and expenses:
Selling, general and administrative	122,574	103,372
Amortization of intangible assets	19,411	10,268
Operating income	69,792	67,829
Other income (expense):
Interest income	179	282
Interest expense	(9,987)	(11,191)
Other income, net	6,306	6,120
Income from continuing operations, before income taxes	66,290	63,040
Provision for income taxes	10,602	9,772
Income from continuing operations, net of income taxes	55,688	53,268
Loss from discontinued operations, net of income taxes	0	(23)
Net income	55,688	53,245
Less: Net income attributable to noncontrolling interests	555	614
Net income attributable to common shareholders	$ 55,133	$ 52,631
Basic:
Continuing operations attributable to common shareholders (in dollars per share)	$ 1.14	$ 1.10
Discontinued operations (in dollars per share)	0.00	0.00
Net income attributable to common shareholders (in dollars per share)	1.14	1.10
Diluted:
Continuing operations attributable to common shareholders (in dollars per share)	1.11	1.08
Discontinued operations (in dollars per share)	0.00	0.00
Net income attributable to common shareholders (in dollars per share)	$ 1.11	$ 1.08
Weighted-average shares outstanding—Basic (in shares)	48,458	47,785
Weighted-average shares outstanding—Diluted (in shares)	49,462	48,828
Service
Total revenue	$ 450,942	$ 345,454
Costs and expenses:
Cost of services provided (excluding amortization of intangible assets)	316,800	243,808
Product
Total revenue	153,627	148,516
Costs and expenses:
Cost of services provided (excluding amortization of intangible assets)	$ 75,992	$ 68,693

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 55,688	$ 53,245
Other comprehensive income (loss):
Foreign currency translation adjustment and other	9,885	25,431
Amortization of net loss and prior service benefit included in net periodic cost for pension and other post-retirement benefit plans	374	459
Comprehensive income, before income taxes	65,947	79,135
Less: Income tax (benefit) expense related to items of other comprehensive income	(102)	1,722
Comprehensive income, net of income taxes	66,049	77,413
Less: Comprehensive income related to noncontrolling interests, net of income taxes	1,013	1,178
Comprehensive income attributable to common shareholders, net of income taxes	$ 65,036	$ 76,235

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018
Current assets:
Cash and cash equivalents	$ 126,316	$ 195,442
Trade receivables, net	495,501	472,248
Inventories	129,765	127,892
Prepaid assets	58,549	53,447
Other current assets	56,051	48,807
Total current assets	866,182	897,836
Property, plant and equipment, net	907,367	932,877
Right-of-use asset-operating leases	130,704
Goodwill	1,245,848	1,247,133
Client relationships and other intangible assets, net	594,759	610,888
Deferred tax assets	23,772	23,386
Other assets	158,005	143,759
Total assets	3,926,637	3,855,879
Current liabilities:
Current portion of long-term debt and finance leases	30,655	31,416
Accounts payable	78,523	66,250
Accrued compensation	82,174	137,212
Deferred revenue	137,886	145,139
Accrued liabilities	109,049	106,925
Other current liabilities	91,472	71,280
Total current liabilities	529,759	558,222
Long-term debt, net and finance leases	1,540,833	1,636,598
Right-of-use liability-operating leases	109,054
Deferred tax liabilities	151,881	143,635
Other long-term liabilities	173,562	179,121
Total liabilities	2,505,089	2,517,576
Commitments and contingencies (Note 17)
Redeemable noncontrolling interest	20,519	18,525
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 48,884 shares issued and 48,747 shares outstanding as of March 30, 2019, and 48,210 shares issued and 48,209 shares outstanding as of December 29, 2018	489	482
Additional paid-in capital	1,481,011	1,447,512
Retained earnings	97,229	42,096
Treasury stock, at cost, 137 and 1 shares, as of March 30, 2019 and December 29, 2018, respectively	(17,815)	(55)
Accumulated other comprehensive loss	(162,800)	(172,703)
Total equity attributable to common shareholders	1,398,114	1,317,332
Noncontrolling interest	2,915	2,446
Total equity	1,401,029	1,319,778
Total liabilities, redeemable noncontrolling interest, and equity	3,926,637	3,855,879
Client relationships, net
Current assets:
Client relationships and other intangible assets, net	525,108	537,945
Other intangible assets, net
Current assets:
Client relationships and other intangible assets, net	$ 69,651	$ 72,943

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Mar. 30, 2019	Dec. 29, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	48,884,000	48,210,000
Common stock, shares outstanding (in shares)	48,747,000	48,209,000
Treasury stock (in shares)	137,000	1,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Cash flows relating to operating activities
Net income	$ 55,688	$ 53,245
Loss from discontinued operations, net of income taxes	0	(23)
Income from continuing operations, net of income taxes	55,688	53,268
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
Depreciation and amortization	45,358	33,210
Stock-based compensation	12,899	10,541
Deferred income taxes	7,781	(782)
Gain on venture capital investments	(10,575)	(6,451)
Other, net	(380)	3,932
Changes in assets and liabilities:
Trade receivables, net	(23,127)	(3,780)
Inventories	(2,520)	(3,501)
Accounts payable	10,245	(1,076)
Accrued compensation	(55,114)	(30,991)
Deferred revenue	(14,405)	(18,292)
Customer contract deposits	(5,866)	23,566
Other assets and liabilities, net	(5,125)	407
Net cash provided by operating activities	14,859	60,051
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(989)	(20,216)
Capital expenditures	(16,731)	(27,726)
Purchases of investments and contributions to venture capital investments	(2,419)	(5,268)
Proceeds from sale of investments	15	28,596
Other, net	(689)	(50)
Net cash used in investing activities	(20,813)	(24,664)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	290,111	1,080,299
Proceeds from exercises of stock options	21,832	20,041
Payments on long-term debt, revolving credit facility, and finance lease obligations	(360,658)	(1,096,795)
Payments on debt financing costs	0	(4,932)
Purchase of treasury stock	(17,760)	(13,549)
Other, net	(2,608)	0
Net cash used in financing activities	(69,083)	(14,936)
Discontinued operations
Net cash used in operating activities from discontinued operations	0	(636)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	6,025	4,254
Net change in cash, cash equivalents, and restricted cash	(69,012)	24,069
Cash, cash equivalents, and restricted cash, beginning of period	197,318	166,331
Cash, cash equivalents, and restricted cash, end of period	128,306	190,400
Supplemental cash flow information:
Cash, cash equivalents, and restricted cash, end of period	$ 197,318	$ 166,331

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total Equity Attributable to Common Shareholders	Noncontrolling Interest
Beginning balance (in shares) at Dec. 30, 2017		87,495				40,093
Beginning balance at Dec. 30, 2017	$ 1,047,407	$ 875	$ 2,560,192	$ 288,658	$ (144,731)	$ (1,659,914)	$ 1,045,080	$ 2,327
Increase (Decrease) in Stockholders' Equity
Net income	53,095			52,631			52,631	464
Other comprehensive income	23,604				23,604		23,604
Reclassification due to adoption of ASU 2018-02	0			3,330	(3,330)
Issuance of stock under employee compensation plans (in shares)		630
Issuance of stock under employee compensation plans	20,094	$ 6	20,088				20,094
Acquisition of treasury shares (in shares)						127
Acquisition of treasury shares	(13,549)					$ (13,549)	(13,549)
Stock-based compensation	10,541		10,541				10,541
Ending balance (in shares) at Mar. 31, 2018		88,125				40,220
Ending balance at Mar. 31, 2018	1,142,617	$ 881	2,590,821	346,044	(124,457)	$ (1,673,463)	1,139,826	2,791
Beginning balance (in shares) at Dec. 29, 2018		48,210				1
Beginning balance at Dec. 29, 2018	1,319,778	$ 482	1,447,512	42,096	(172,703)	$ (55)	1,317,332	2,446
Increase (Decrease) in Stockholders' Equity
Net income	55,602			55,133			55,133	469
Other comprehensive income	9,903				9,903		9,903
Adjustment of redeemable noncontrolling interest to redemption value	(1,451)		(1,451)				(1,451)
Issuance of stock under employee compensation plans (in shares)		674
Issuance of stock under employee compensation plans	22,058	$ 7	22,051				22,058
Acquisition of treasury shares (in shares)						136
Acquisition of treasury shares	(17,760)					$ (17,760)	(17,760)
Stock-based compensation	12,899		12,899				12,899
Ending balance (in shares) at Mar. 30, 2019		48,884				137
Ending balance at Mar. 30, 2019	$ 1,401,029	$ 489	$ 1,481,011	$ 97,229	$ (162,800)	$ (17,815)	$ 1,398,114	$ 2,915

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Mar. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2018. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2018 as well as Note 16, “Leases” in this Quarterly Report on Form 10-Q. Newly Adopted Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, “Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” ASU 2018-07 aligns the accounting for share-based payment awards issued to employees and nonemployees as well as improves financial reporting for share-based payments to nonemployees. This standard became effective for the Company in the three months ended March 30, 2019 and did not have a material impact on the consolidated financial statements and related disclosures. In August 2017, the FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815) Targeted Improvements to Accounting for Hedging Activities.” ASU 2017-12 refines and expands hedge accounting for both financial and commodity risks. It also creates more transparency around how economic results are presented, both on the face of the financial statements and in the disclosures. In addition, this ASU makes certain targeted improvements to simplify the application of hedge accounting guidance. This standard became effective for the Company in the three months ended March 30, 2019 and did not have a material impact on the consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard, including subsequently issued amendments, collectively referred to as Accounting Standards Codification (ASC) 842, “Leases”, established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The Company adopted this standard using the modified retrospective transition approach as applied to leases existing as of or entered into after the adoption date (December 30, 2018) in the three months ended March 30, 2019. See Note 16, “Leases” for a discussion of the Company’s adoption of this standard and its impact on the consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computer Arrangement that is a Service Contract.” ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years and will be applied either retrospectively or prospectively. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14, “Compensation Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20).” ASU 2018-14 removes the requirements to disclose the amounts in Accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year and the related party disclosures about the amount of future annual benefits covered by insurance contracts. In addition, the ASU adds the requirement to disclose an explanation for any significant gains and losses related to changes in the benefit obligation for the period. The ASU is effective for fiscal years ending after December 15, 2020 and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes the disclosure requirement for the amount and reasons for transfers between Level 1 and Level 2 fair value measurements as well as the process for Level 3 fair value measurements. In addition, the ASU adds the disclosure requirements for changes in unrealized gains and losses included in Other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period as well as the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. This standard is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and will be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses.” The standard requires a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and requires the modified retrospective approach. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

BUSINESS ACQUISITIONS

3 Months Ended

Mar. 30, 2019

Business Combinations [Abstract]

BUSINESS ACQUISITIONS

Citoxlab

On April 29, 2019, the Company acquired Citoxlab, a non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab will further strengthen the Company’s position as a leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which enhances the Company’s ability to partner with clients across the drug discovery and development continuum. The preliminary purchase price for Citoxlab was €448 million in cash (or approximately $500 million), subject to certain post-closing adjustments that may change the purchase price. The acquisition was funded through a combination of cash on hand and proceeds from the Company’s $2.3B Credit Facility under the multi-currency revolving facility. See Note 9, “Long-Term Debt and Finance Leases.” This business will be reported as part of the Company’s DSA reportable segment. Due to the limited time between the acquisition date and the filing of this Quarterly Report on Form 10-Q, it is not practicable for the Company to disclose either the preliminary allocation of purchase price to assets acquired and liabilities assumed or the pro forma consolidated results of operations as if the Citoxlab acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition after giving effect to certain adjustments. The Company incurred transaction and integration costs in connection with the acquisition of $5.2 million during the three months ended March 30, 2019, which were included in selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

MPI Research

On April 3, 2018, the Company acquired MPI Research, a non-clinical CRO providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. The acquisition enhances the Company’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum. The purchase price for MPI Research was $829.7 million in cash. The acquisition was funded by borrowings on the $2.3B Credit Facility as well as the issuance of the Company’s Senior Notes. See Note 9, “Long-Term Debt and Finance Lease Obligations.” This business is reported as part of the Company’s DSA reportable segment.

The purchase allocation of $800.8 million, net of $27.7 million of cash acquired and a final net working capital adjustment of $1.2 million, was as follows:



	April 3, 2018
	(in thousands)
Trade receivables (contractual amount of $35,073)	$	35,073
Inventories	4,463
Other current assets (excluding cash)	5,893
Property, plant and equipment	128,403
Goodwill	441,656
Definite-lived intangible assets	309,200
Other long-term assets	1,081
Deferred revenue	(23,926		)
Current liabilities	(32,885		)
Deferred tax liabilities	(65,945		)
Other long-term liabilities	(2,213		)
Total purchase price allocation	$	800,800

From the date of the acquisition through March 30, 2019, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation.

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	264,900	13
Developed technology	23,400		3
Backlog	20,900		1
Total definite-lived intangible assets	$	309,200	12

The goodwill resulting from the transaction, $4.1 million of which is deductible for tax purposes due to a prior asset acquisition, is primarily attributable to the potential growth of the Company’s DSA business from customers introduced through MPI Research and the assembled workforce of the acquired business.

The Company incurred transaction and integration costs in connection with the acquisition of $0.1 million and $2.7 million for the three months ended March 30, 2019 and March 31, 2018, respectively, which were primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

The following selected unaudited pro forma consolidated results of operations are presented as if the MPI Research acquisition had occurred as of the beginning of the period immediately preceding the period of acquisition, which is January 1, 2017, after giving effect to certain adjustments. For the three months ended March 31, 2018, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $6.9 million, additional interest expense on borrowings of $2.6 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.



	Three Months Ended
	March 31, 2018
	(in thousands)
Revenue	$	556,091
Net income attributable to common shareholders	49,414

These unaudited pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the dates indicated or that may result in the future. No effect has been given for synergies, if any, that may be realized through the acquisition.

KWS BioTest Limited

On January 11, 2018, the Company acquired KWS BioTest Limited (KWS BioTest), a CRO specializing in in vitro and in vivo discovery testing services for immuno-oncology, inflammatory and infectious diseases. The acquisition enhances the Company’s discovery expertise, with complementary offerings that provide the Company’s customers with additional tools in the active therapeutic research areas of oncology and immunology. The purchase price for KWS BioTest was $20.3 million in cash and was funded by the Company’s various borrowings. In addition to the initial purchase price, the transaction includes aggregate, undiscounted contingent payments of up to £3.0 million based on future performance. During the three months ended September 29, 2018, the terms of these contingent payments were amended, resulting in a fixed payment of £2.0 million, or $2.6 million, which was paid during the three months ended March 30, 2019. The KWS BioTest business is reported as part of the Company’s DSA reportable segment.

The purchase price allocation of $21.5 million, net of $1.0 million of cash acquired and a final net working capital adjustment of $0.4 million, was as follows:



	January 11, 2018
	(in thousands)
Trade receivables (contractual amount of $1,309)	$	1,309
Other current assets (excluding cash)	99
Property, plant and equipment	1,136
Definite-lived intangible assets - client relationships	3,647
Goodwill	17,660
Current liabilities	(1,575		)
Deferred revenue	(151		)
Long-term liabilities	(596		)
Total purchase price allocation	$	21,529

From the date of the acquisition through December 29, 2018, the Company recorded measurement-period adjustments related to the acquisition that resulted in an immaterial change to the purchase price allocation on a consolidated basis. No further adjustments will be made to the purchase price allocation.

The only definite-lived intangible asset relates to client relationships, which will be amortized over a weighted average life of 12 years.

The goodwill resulting from the transaction is primarily attributable to the potential growth of the Company’s DSA business from customers introduced through KWS BioTest and the assembled workforce of the acquired business. The goodwill attributable to KWS BioTest is not deductible for tax purposes.

The Company incurred transaction and integration costs of $0.1 million and $0.4 million in connection with the acquisition for the three months ended March 30, 2019 and March 31, 2018, respectively, which were included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

Pro forma financial information as well as actual revenue and operating income have not been included because KWS BioTest’s financial results are not significant when compared to the Company’s consolidated financial results.

REVENUE FROM CONTRACTS WITH CUSTOMERS

3 Months Ended

Mar. 30, 2019

Revenue from Contract with Customer [Abstract]

REVENUE FROM CONTRACTS WITH CUSTOMERS

Revenue Recognition

Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer (“transaction price”).

To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the amount to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Generally, the Company does not extend payment terms beyond one year. Applying the practical expedient, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component for the three months ended March 30, 2019.

Contracts with customers may contain multiple performance obligations. For such arrangements, the transaction price is allocated to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.

Contracts are often modified to account for changes in contract specifications and requirements. Contract modifications exist when the modification either creates new, or changes existing, enforceable rights and obligations. Generally, when contract modifications create new performance obligations, the modification is considered to be a separate contract and revenue is recognized prospectively. When contract modifications change existing performance obligations, the existing transaction price and measure of progress for the performance obligation to which it relates is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) on a cumulative catch-up basis.

Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Service revenue is generally recognized over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. Depending on which better depicts the transfer of value to the customer, the Company generally measures its progress using either cost-to-cost (input method) or right-to-invoice (output method). The Company uses the cost-to-cost measure of progress when it best depicts the transfer of value to the customer which occurs as the Company incurs costs on its contract, generally related to fixed fee service contracts. Under the cost-to-cost measure of progress, the extent of progress towards completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. The costs calculation includes variables such as labor hours, allocation of overhead costs, research model costs, and subcontractor costs. Revenue is recorded proportionally as costs are incurred. The right-to-invoice measure of progress is generally related to rate per unit contracts, as the extent of progress towards completion is measured based on discrete service or time-based increments, such as samples tested or labor hours incurred. Revenue is recorded in the amount invoiced since that amount corresponds directly to the value of the Company’s performance to date.

Disaggregation of Revenue

The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Major Products/Service Lines:
RMS	$	137,172	$	133,958
DSA	354,197		259,992
Manufacturing	113,200		100,020
Total revenue	$	604,569	$	493,970



Timing of Revenue Recognition:
RMS
Services and products transferred over time	$	54,813	$	48,726
Services and products transferred at a point in time	82,359		85,232
DSA
Services and products transferred over time	354,078		259,744
Services and products transferred at a point in time	119		248
Manufacturing
Services and products transferred over time	31,896		28,571
Services and products transferred at a point in time	81,304		71,449
Total revenue	$	604,569	$	493,970

RMS

The RMS business generates revenue through the commercial production and sale of research models and the provision of services related to the maintenance and monitoring of research models and management of clients’ research operations. Revenue from the sale of research models is recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the shipping terms of a contract. Revenue generated from research models services is recognized over time and is typically based on a right-to-invoice measure of progress (output method) as invoiced amounts correspond directly to the value of the Company’s performance to date.

DSA

The Discovery and Safety Assessment business provides a full suite of integrated drug discovery services directed at the identification, screening and selection of a lead compound for drug development and offers a full range of safety assessment services including bioanalysis, drug metabolism, pharmacokinetics, toxicology and pathology. Discovery and Safety Assessment services revenue is generally recognized over time using the cost-to-cost or right to invoice measures of progress, primarily representing fixed fee service contracts and per unit service contracts, respectively.

Manufacturing

The Manufacturing business includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services; Biologics Testing Services (Biologics), which performs specialized testing of biologics; and Avian Vaccine Services (Avian), which supplies specific-pathogen-free chicken eggs and chickens. Species identification service revenue is generally recognized at a point in time as identifications are completed by the Company. Biologics service revenue is generally recognized over time using the cost-to-cost measure of progress. Microbial Solutions and Avian product sales are generally recognized at a point in time when the customer obtains control of the product, which may be upon shipment or upon delivery based on the contractual shipping terms of a contract.

Transaction Price Allocated to Future Performance Obligations

The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 30, 2019. Excluded from the disclosure is the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed.

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 30, 2019:



	Revenue Expected to be Recognized in Future Periods
	Less than 1 Year		1 to 3 Years		4 to 5 Years		Beyond 5 Years		Total
	(in thousands)
DSA	$	161,751	$	103,493	$	8,246	$	548	$	274,038
Manufacturing	7,158		20,363		1,706		81		29,308
Total	$	168,909	$	123,856	$	9,952	$	629	$	303,346

Contract Balances from Contracts with Customers

The timing of revenue recognition, billings and cash collections results in billed receivables (client receivables), contract assets (unbilled revenue), contract liabilities (current and non-current deferred revenue), and customer deposits on the unaudited condensed consolidated balance sheets. The Company’s payment terms are generally 30 days in the United States and consistent with prevailing practice in international markets. A contract asset is recorded when a right to consideration in exchange for goods or services transferred to a customer is conditioned other than the passage of time. Client receivables are recorded separately from contract assets since only the passage of time is required before consideration is due. A contract liability is recorded when consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:



	March 30, 2019		December 29, 2018
	(in thousands)
Balances from contracts with customers:
Client receivables	$	377,188	$	370,131
Contract assets (unbilled revenue)	120,607		105,216
Contract liabilities (current and long-term deferred revenue)	166,705		179,559
Contract liabilities (customer contract deposits)	32,380		38,245

When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. As of March 30, 2019, the Company excluded approximately $12 million of unpaid advanced client billings from both client receivables and deferred revenue and approximately $32 million of advanced client payments have been presented as customer contract deposits within other current liabilities in the accompanying unaudited condensed consolidated balance sheets.

Other changes in the contract asset and the contract liability balances during the three months ended March 30, 2019 were as follows:

(i) Cumulative catch-up adjustments to revenue that affect the corresponding contract asset or contract liability, including adjustments arising from a change in the measure of progress, a change in an estimate of the transaction price (including any changes in the assessment of whether an estimate of variable consideration is constrained), or a contract modification:

During the three months ended March 30, 2019, an immaterial cumulative catch-up adjustment to revenue was recorded.

(ii) A change in the time frame for a right to consideration to become unconditional (that is, for a contract asset to be recorded as a client receivable):

Approximately 70% of unbilled revenue as of December 29, 2018 was billed during the three months ended March 30, 2019.

(iii) A change in the time frame for a performance obligation to be satisfied (that is, for the recognition of revenue arising from a contract liability):

Approximately 60% of contract liabilities as of December 29, 2018 were recognized as revenue during the three months ended March 30, 2019.

SEGMENT INFORMATION

3 Months Ended

Mar. 30, 2019

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company’s three reportable segments are Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

The following table presents revenue and other financial information by reportable segment:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS
Revenue	$	137,172	$	133,958
Operating income	37,832		38,527
Depreciation and amortization	4,322		4,853
Capital expenditures	4,112		4,625
DSA
Revenue	$	354,197	$	259,992
Operating income	46,705		40,859
Depreciation and amortization	33,784		20,787
Capital expenditures	8,848		12,802
Manufacturing
Revenue	$	113,200	$	100,020
Operating income	31,499		28,523
Depreciation and amortization	5,805		5,736
Capital expenditures	3,606		6,834

The following table presents reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts:



	Operating Income						Depreciation and Amortization				Capital Expenditures
	March 30, 2019			March 31, 2018			March 30, 2019		March 31, 2018		March 30, 2019		March 31, 2018
	(in thousands)
Three Months Ended:
Total reportable segments	$	116,036		$	107,909		$	43,911	$	31,376	$	16,566	$	24,261
Unallocated corporate	(46,244		)	(40,080		)	1,447		1,834		165		3,465
Total consolidated	$	69,792		$	67,829		$	45,358	$	33,210	$	16,731	$	27,726

Revenue for each significant product or service offering is as follows:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS	$	137,172	$	133,958
DSA	354,197		259,992
Manufacturing	113,200		100,020
Total revenue	$	604,569	$	493,970

A summary of unallocated corporate expense consists of the following:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Stock-based compensation	$	8,274	$	6,991
Compensation, benefits, and other employee-related expenses	22,038		20,596
External consulting and other service expenses	3,810		2,934
Information technology	2,723		2,465
Depreciation	1,447		1,834
Acquisition and integration	5,472		2,864
Other general unallocated corporate	2,480		2,396
Total unallocated corporate expense	$	46,244	$	40,080

Other general unallocated corporate expense consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

Revenue by geographic area is as follows:



	U.S.		Europe		Canada		Asia Pacific		Other		Consolidated
	(in thousands)
Three Months Ended:
March 30, 2019	$	350,176	$	166,365	$	53,979	$	33,179	$	870	$	604,569
March 31, 2018	248,980		160,826		48,578		34,520		1,066		493,970

Included in the Asia Pacific category above are operations located in China, Japan, Korea, Australia, Singapore, and India. Included in the Other category above are operations located in Brazil and Israel. Revenue represents sales originating in entities physically located in the identified geographic area.

SUPPLEMENTAL BALANCE SHEET INFORMATION

3 Months Ended

Mar. 30, 2019

Supplemental Balance Sheet Information [Abstract]

SUPPLEMENTAL BALANCE SHEET INFORMATION

The composition of trade receivables, net is as follows:



	March 30, 2019			December 29, 2018
	(in thousands)
Client receivables	$	377,188		$	370,131
Unbilled revenue	120,607			105,216
Total	497,795			475,347
Less: Allowance for doubtful accounts	(2,294		)	(3,099		)
Trade receivables, net	$	495,501		$	472,248

The composition of inventories is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Raw materials and supplies	$	22,118	$	22,378
Work in process	20,710		21,732
Finished products	86,937		83,782
Inventories	$	129,765	$	127,892

The composition of other current assets is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Prepaid income tax	$	54,153	$	47,157
Investments	907		885
Restricted cash	491		465
Other	500		300
Other current assets	$	56,051	$	48,807

The composition of other assets is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Venture capital investments	$	100,666	$	88,591
Life insurance policies	34,939		32,340
Restricted cash	1,499		1,411
Other	20,901		21,417
Other assets	$	158,005	$	143,759

The composition of other current liabilities is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Current portion of right-of-use liabilities-operating leases	$	18,912	$	—
Accrued income taxes	25,725		24,120
Customer contract deposits	32,380		38,245
Other	14,455		8,915
Other current liabilities	$	91,472	$	71,280

The composition of other long-term liabilities is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
U.S. Transition Tax	$	52,066	$	52,064
Long-term pension liability	24,589		24,671
Accrued executive supplemental life insurance retirement plan	36,522		36,086
Long-term deferred revenue	28,819		34,420
Other	31,566		31,880
Other long-term liabilities	$	173,562	$	179,121

VENTURE CAPITAL INVESTMENTS	3 Months Ended
VENTURE CAPITAL INVESTMENTS	Mar. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL INVESTMENTS	VENTURE CAPITAL INVESTMENTS The Company invests in several venture capital funds that invest in start-up companies, primarily in the life sciences industry. The Company’s ownership interest in these funds ranges from less than 1% to 12.0%. The Company accounts for the investments in limited partnerships (LPs), which are variable interest entities, under the equity method of accounting. For publicly-held investments in the LPs, the Company adjusts for changes in fair market value based on reported share holdings at the end of each fiscal quarter. The Company is not the primary beneficiary because it has no power to direct the activities that most significantly affect the LPs’ economic performance. The Company accounts for the investments in limited liability companies, which are not variable interest entities, under the equity method of accounting. The Company’s total commitment to the venture capital funds as of March 30, 2019 was $124.4 million, of which the Company funded $71.4 million through that date. The Company received dividends totaling $0.8 million and $7.1 million for the three months ended March 30, 2019 and March 31, 2018, respectively. The Company recognized gains of $10.6 million and $6.5 million related to the venture capital investments for the three months ended March 30, 2019 and March 31, 2018, respectively. Gains and losses are recorded in Other income, net in the accompanying unaudited condensed consolidated statements of income.

FAIR VALUE

3 Months Ended

Mar. 30, 2019

Fair Value Disclosures [Abstract]

FAIR VALUE

The Company has certain assets and liabilities recorded at fair value, which have been classified as Level 1, 2, or 3 within the fair value hierarchy:


•	Level 1 - Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access,


•	Level 2 - Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates,


•	Level 3 - Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The fair value hierarchy level is determined by asset and class based on the lowest level of significant input. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the three months ended March 30, 2019 and March 31, 2018, there were no transfers between levels.

Valuation methodologies used for assets and liabilities measured or disclosed at fair value are as follows:


•	Cash equivalents - Valued at market prices determined through third-party pricing services;


•	Mutual funds - Valued at the unadjusted quoted net asset value of shares held by the Company;


•	Foreign currency forward contracts - Valued using market observable inputs, such as forward foreign exchange points and foreign exchanges rates;


•	Life insurance policies - Valued at cash surrender value based on the fair value of underlying investments;

•

Debt instruments - The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. The book value of the Company’s 5.5% Senior Notes (Senior Notes) due in 2026, which are fixed rate debt, are carried at amortized cost. Fair value of the Senior Notes is based on quoted market prices and on borrowing rates available to the Company; and


•	Contingent consideration - Valued based on a probability weighting of the future cash flows associated with the potential outcomes.

Assets and liabilities measured at fair value on a recurring basis are summarized below:



	March 30, 2019
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	2,521	$	—	$	2,521
Other assets:
Life insurance policies	—		27,335		—		27,335
Total assets measured at fair value	$	—	$	29,856	$	—	$	29,856

Other current liabilities measured at fair value:
Contingent consideration	$	—	$	—	$	2,497	$	2,497



	December 29, 2018
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	45,982	$	—	$	45,982
Other assets:
Life insurance policies	—		24,541		—		24,541
Total assets measured at fair value	$	—	$	70,523	$	—	$	70,523

Other current liabilities:
Contingent consideration	$	—	$	—	$	3,033	$	3,033
Foreign currency forward contract	—		1,319		—		1,319
Total liabilities measured at fair value	$	—	$	1,319	$	3,033	$	4,352

Contingent Consideration

The following table provides a rollforward of the contingent consideration related to previous business acquisitions. See Note 2, “Business Acquisitions.”



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Beginning balance	$	3,033		$	298
Additions	2,000			2,746
Payments	(2,610		)	—
Foreign currency translation	74			9
Ending balance	$	2,497		$	3,053

The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement of certain financial targets and a discount rate. Increases or decreases in any of the probabilities of success would result in a higher or lower fair value measurement, respectively. Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively.

Debt Instruments

The book value of the Company’s term and revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.

As of both March 30, 2019 and December 29, 2018, the book value of the Company’s Senior Notes, which is a fixed rate obligation carried at amortized cost, was $500.0 million. The fair value of the Company’s Senior Notes as of March 30, 2019 and December 29, 2018 was $520.0 million and $495.0 million, respectively. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table provides a rollforward of the Company’s goodwill:



			Adjustments to Goodwill
	December 29, 2018			Foreign Exchange			March 30, 2019
	(in thousands)
RMS	$	56,968		$	278		$	57,246
DSA	1,051,470			(2,341		)	1,049,129
Manufacturing	138,695			778			139,473
Goodwill	$	1,247,133		$	(1,285	)	$	1,245,848

Intangible Assets, Net

The following table displays intangible assets, net by major class:



	March 30, 2019							December 29, 2018
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	(in thousands)
Backlog	$	20,900	$	(19,238	)	$	1,662	$	20,900	$	(18,691	)	$	2,209
Technology	102,038		(44,682		)	57,356		101,506		(41,870		)	59,636
Trademarks and trade names	8,411		(4,692		)	3,719		8,331		(4,640		)	3,691
Other	17,471		(10,557		)	6,914		17,448		(10,041		)	7,407
Other intangible assets	148,820		(79,169		)	69,651		148,185		(75,242		)	72,943
Client relationships	797,014		(271,906		)	525,108		791,725		(253,780		)	537,945
Intangible assets	$	945,834	$	(351,075	)	$	594,759	$	939,910	$	(329,022	)	$	610,888

The decrease in intangible assets, net during the three months ended March 30, 2019 related to the normal amortization over the useful lives.

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS

3 Months Ended

Mar. 30, 2019

Debt Disclosure [Abstract]

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS

Long-Term Debt

Long-term debt, net consists of the following:



	March 30, 2019			December 29, 2018
	(in thousands)
Term loans	$	721,875		$	731,250
Revolving facility	335,976			397,452
Senior Notes	500,000			500,000
Other debt	101			26,286
Finance leases	28,939			29,240
Total debt and finance leases	1,586,891			1,684,228
Less:
Current portion of long-term debt	28,225			28,228
Current portion of finance leases	2,430			3,188
Current portion of long-term debt and finance leases	30,655			31,416
Long-term debt and finance leases	1,556,236			1,652,812
Debt discount and debt issuance costs	(15,403		)	(16,214		)
Long-term debt, net and finance leases	$	1,540,833		$	1,636,598

As of March 30, 2019 and December 29, 2018, the weighted average interest rate on the Company’s debt was 3.77% and 4.24%, respectively.

Term Loans and Revolving Facility

On March 26, 2018, the Company amended and restated its $1.65 billion credit facility creating a $2.3 billion credit facility ($2.3B Credit Facility) which extends the maturity date for the credit facility. The $2.3B Credit Facility provides for a $750.0 million term loan and a $1.55 billion multi-currency revolving facility. The amendment was accounted for as a debt modification. In connection with the transaction, the Company capitalized approximately $6.2 million within Long-term debt, net and finance leases in the accompanying unaudited condensed consolidated balance sheets and expensed approximately $1.0 million of debt issuance costs recorded within Interest expense in the accompanying unaudited condensed consolidated statements of income.

The term loan facility matures in 19 quarterly installments with the last installment due March 26, 2023. The revolving facility matures on March 26, 2023, and requires no scheduled payment before that date. Under specified circumstances, the Company has the ability to increase the term loan and/or revolving facility by up to $1.0 billion in the aggregate.

The interest rates applicable to the term loan and revolving facility under the $2.3B Credit Facility are, at the Company’s option, equal to either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted LIBOR rate plus 1.0%) or the adjusted LIBOR rate, plus an interest rate margin based upon the Company’s leverage ratio.

The $2.3B Credit Facility includes certain customary representations and warranties, events of default, notices of material adverse changes to the Company’s business and negative and affirmative covenants. These covenants include (1) maintenance of a ratio of consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) less capital expenditures to consolidated cash interest expense, for any period of four consecutive fiscal quarters, of no less than 3.50 to 1.0 as well as (2) maintenance of a ratio of consolidated indebtedness to consolidated EBITDA for any period of four consecutive fiscal quarters, of no more than 4.50 to 1.0 with step downs to 3.50 to 1.0 by the last day of the first quarter of 2020. As of March 30, 2019, the Company was compliant with all covenants.

The obligations of the Company under the $2.3B Credit Facility are collateralized by substantially all of the assets of the Company.

During the three months ended March 30, 2019, the Company had a $343.3 million U.S. dollar denominated loan borrowed by a non-U.S. Euro functional currency entity under the Company’s $2.3B Credit Facility, which resulted in foreign currency losses recognized in Other income, net. The Company entered into foreign exchange forward contracts to limit its foreign currency exposures related to these borrowings. As of March 30, 2019, the Company did not have any outstanding borrowings in a currency different than its respective functional currency. See Note 14, “Foreign Currency Contracts”, for further discussion.

The acquisition of Citoxlab on April 29, 2019 for €448 million in cash (or approximately $500 million) was funded through a combination of cash on hand and proceeds from the $2.3B Credit Facility under the multi-currency revolving facility.

Senior Notes Offering

On April 3, 2018, the Company entered into an indenture (Indenture) with MUFG Union Bank, N.A., (Trustee) in connection with the offering of $500.0 million in aggregate principal amount of the Company’s 5.5% Senior Notes (Senior Notes), due in 2026, in an unregistered offering. Under the terms of the Indenture, interest on the Senior Notes is payable semi-annually on April 1 and October 1, beginning on October 1, 2018. The Senior Notes are guaranteed fully and unconditionally, jointly and severally on a senior unsecured basis by the Company and certain of its U.S. subsidiaries. In connection with the transaction, the Company incurred approximately $7.4 million of debt issuance costs within Long-term debt, net and finance leases in the accompanying unaudited condensed consolidated balance sheets.

The Company may redeem all or part of the Senior Notes at any time prior to April 1, 2021, at its option, at a redemption price equal to 100% of the principal amount of such Senior Notes plus the Applicable Premium (as defined in the Indenture). The Company may also redeem up to 40% of the Senior Notes with the proceeds of certain equity offerings completed before April 1, 2021, at a redemption price equal to 105.5% of the principal amount of such Senior Notes. On or after April 1, 2021, the Company may on any one or more occasions redeem all or a part of the Senior Notes, at the redemption prices specified in the Indenture based on the applicable date of redemption. Upon the occurrence of a Change of Control Triggering Event (as defined in the Indenture), the Company will be required to offer to repurchase the Senior Notes at a purchase price equal to 101% of the aggregate principal amount of such Senior Notes. Any redemption of the Senior Notes would also require settlement of accrued and unpaid interest, if any, up to but excluding the redemption date.

The Indenture contains certain covenants including, but not limited to, limitations and restrictions on the ability of the Company and its U.S. subsidiaries to (i) create certain liens, (ii) enter into any Sale and Leaseback Transaction (as defined in the Indenture) with respect to any property, and (iii) merge, consolidate, sell or otherwise dispose of all or substantially all of their assets. These covenants are subject to a number of conditions, qualifications, exceptions and limitations. Any event of default, as defined, could result in the acceleration of the repayment of the obligations.

Net proceeds from the Senior Notes of $493.8 million were used to partially repay the outstanding revolving credit facility on April 3, 2018.

Commitment Letter

On February 12, 2018, the Company secured an $830 million commitment under a 364-day senior unsecured bridge loan facility (the Bridge Facility) for the purpose of financing the acquisition of MPI Research. The Bridge Facility was terminated as of April 3, 2018 upon the successful acquisition of MPI Research. Debt issuance costs of $1.8 million, which were capitalized upon the execution of the Bridge Facility, were expensed upon termination of the agreement on April 3, 2018. In addition, the Company incurred and expensed $2.0 million of fees pertaining to a temporary backstop facility related to the negotiation of the Credit Facility during the three months ended March 31, 2018. These costs were included in Interest expense in the accompanying unaudited condensed consolidated statements of income.

Letters of Credit

As of both March 30, 2019 and December 29, 2018, the Company had $6.5 million in outstanding letters of credit.

Finance Lease Obligations

The Company’s finance lease obligations amounted to $28.9 million and $29.2 million as of March 30, 2019 and December 29, 2018, respectively. See Note 16, “Leases” for further discussion.

EQUITY AND NONCONTROLLING INTEREST

3 Months Ended

Mar. 30, 2019

Equity [Abstract]

EQUITY AND NONCONTROLLING INTEREST

EQUITY AND NONCONTROLLING INTERESTS

Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Numerator:
Income from continuing operations, net of income taxes	$	55,688	$	53,268
Loss from discontinued operations, net of income taxes	—		(23		)
Less: Net income attributable to noncontrolling interests	555		614
Net income attributable to common shareholders	$	55,133	$	52,631

Denominator:
Weighted-average shares outstanding - Basic	48,458		47,785
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock	1,004		1,043
Weighted-average shares outstanding - Diluted	49,462		48,828

Options to purchase 0.4 million and 0.5 million shares for the three months ended March 30, 2019 and March 31, 2018, respectively, as well as a non-significant number of restricted shares, restricted stock units (RSUs), and performance share units (PSUs), were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Basic weighted-average shares outstanding for the three months ended March 30, 2019 and March 31, 2018 excluded the impact of 1.0 million and 1.1 million shares, respectively, of non-vested restricted stock and RSUs.

Treasury Shares

During the three months ended March 30, 2019 and March 31, 2018, the Company did not repurchase any shares under its authorized stock repurchase program. As of March 30, 2019, the Company had $129.1 million remaining on the authorized stock repurchase program.

The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. During the three months ended March 30, 2019 and March 31, 2018, the Company acquired 0.1 million shares for $17.8 million and 0.1 million shares for $13.5 million, respectively, from such netting.

Accumulated Other Comprehensive Income (Loss)

Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:



	Foreign Currency Translation Adjustment and Other			Pension and Other Post-Retirement Benefit Plans			Total
	(in thousands)
December 29, 2018	$	(102,199	)	$	(70,504	)	$	(172,703	)
Other comprehensive income before reclassifications	9,427			—			9,427
Amounts reclassified from accumulated other comprehensive loss	—			374			374
Net current period other comprehensive income	9,427			374			9,801
Income tax (benefit) expense	(182		)	80			(102		)
March 30, 2019	$	(92,590	)	$	(70,210	)	$	(162,800	)

Nonredeemable Noncontrolling Interest

The Company has an investment in an entity whose financial results are consolidated in the Company’s financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as noncontrolling interest. The activity within the nonredeemable noncontrolling interest was immaterial during the three months ended March 30, 2019 and March 31, 2018.

Redeemable Noncontrolling Interest

The Company’s redeemable noncontrolling interest in Vital River is 13%.

The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 13% equity interest at a contractually defined redemption value, subject to a redemption floor (embedded derivative). These rights are currently exercisable. The redeemable noncontrolling interest is measured at the greater of the amount that would be paid if settlement occurred as of the balance sheet date based on the contractually defined redemption value ($20.5 million as of March 30, 2019) and the carrying amount adjusted for net income (loss) attributable to the noncontrolling interest. As the noncontrolling interest holders have the ability to require the Company to purchase the remaining 13% interest, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The agreement does not limit the amount that the Company could be required to pay to purchase the remaining 13% equity interest.

The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interest:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Beginning balance	$	18,525	$	16,609
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest	85		150
Adjustment to redemption value	1,451		—
Foreign currency translation	458		564
Ending balance	$	20,519	$	17,323

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rates for the three months ended March 30, 2019 and March 31, 2018 were 16.0% and 15.5%, respectively. The slight increase in the 2019 period compared to the 2018 period was primarily attributable to tax benefits from favorable tax authority rulings in the 2018 period, partially offset by increased tax benefits from stock-based compensation deductions in the 2019 period. For the three months ended March 30, 2019, the Company’s unrecognized tax benefits increased by $0.7 million to $19.5 million, primarily due to an additional quarter of Canadian Scientific Research and Experimental Development Credit reserves as well as unfavorable foreign exchange. For the three months ended March 30, 2019, the unrecognized income tax benefits that would impact the effective tax rate increased by $0.5 million to $18.1 million, for the same reasons listed above. The accrued interest on unrecognized tax benefits was $2.9 million at March 30, 2019. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by up to $8.2 million over the next twelve-month period, primarily due to the outcome of pending tax audits. The Company conducts business in several tax jurisdictions. As a result, it is subject to tax audits in jurisdictions including the U.S., U.K., China, France, Germany, Canada, Japan and India. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2015. The Company and certain of its subsidiaries have ongoing tax controversies with various tax authorities in the U.S., Canada, Japan, India and France. The Company does not anticipate resolution of these audits will have a material impact on its financial statements.

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS

3 Months Ended

Mar. 30, 2019

Retirement Benefits [Abstract]

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS

The following table provides the components of net periodic cost for the Company’s pension, deferred compensation and executive supplemental life insurance retirement plans:



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Service cost	$	630		$	846
Interest cost	2,875			2,833
Expected return on plan assets	(3,235		)	(3,877		)
Amortization of prior service cost (credit)	91			(181		)
Amortization of net loss	489			645
Net periodic cost	$	850		$	266

Service cost is recorded as an operating expense within the accompanying unaudited condensed consolidated statements of income. All other components of net periodic costs are recorded in Other income, net in the accompanying unaudited condensed consolidated statements of income. The net periodic cost for the Company’s other post-retirement benefit plan for the three months ended March 30, 2019 and March 31, 2018 was not significant.

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 30, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

The Company has stock-based compensation plans under which employees and non-employee directors may be granted stock-based awards such as stock options, restricted stock, RSUs, and PSUs.

The following table provides stock-based compensation by the financial statement line item in which it is reflected:



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Cost of revenue	$	1,949		$	1,413
Selling, general and administrative	10,950			9,128
Stock-based compensation, before income taxes	12,899			10,541
Provision for income taxes	(2,047		)	(2,116		)
Stock-based compensation, net of income taxes	$	10,852		$	8,425

During the three months ended March 30, 2019, the Company granted stock options representing 0.4 million common shares with a per-share weighted-average grant date fair value of $34.00, RSUs representing 0.2 million common shares with a per-share weighted-average grant date fair value of $144.35, and PSUs representing 0.2 million common shares with a per-share weighted-average grant date fair value of $162.74. The maximum number of common shares to be issued upon vesting of PSUs granted during the three months ended March 30, 2019 is 0.3 million.

FOREIGN CURRENCY CONTRACT

3 Months Ended

Mar. 30, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FOREIGN CURRENCY CONTRACT

FOREIGN CURRENCY CONTRACTS

The Company entered into foreign exchange forward contracts during the three months ended March 30, 2019 and December 29, 2018 to limit its foreign currency exposure related to a U.S. dollar denominated loan borrowed by a non-U.S. Euro functional currency entity under the $2.3B Credit Facility. These contracts are not designated as hedging instruments. Any gains or losses on these forward contracts are recognized immediately in Interest expense.

The open contract at December 29, 2018, which had a duration of approximately 3 months, was recorded at fair value in the Company’s accompanying unaudited condensed consolidated balance sheets. The notional amount and fair value of the open contract is summarized as follows:



	Notional Amount		Fair Value			Balance Sheet Location
	(in thousands)
December 29, 2018	$	343,300	$	(1,319	)	Other current liabilities

The Company had no open forward contracts related to a U.S. dollar denominated loan borrowed by a non-U.S. Euro functional currency at March 30, 2019.

The following table summarizes the effect of the foreign exchange forward contract on the Company’s unaudited condensed consolidated statements of income:



	Three Months Ended
	March 30, 2019					March 31, 2018
Location of hedge gain (loss)	Financial statement caption amount			Amount of gain (loss)		Financial statement caption amount			Amount of gain (loss)
	(in thousands)
Interest expense	$	(9,987	)	$	8,917	$	(11,191	)	$	—

RESTRUCTURING AND ASSET IMPAIRMENT

3 Months Ended

Mar. 30, 2019

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND ASSET IMPAIRMENT

RESTRUCTURING AND ASSET IMPAIRMENTS

Global Restructuring Initiatives

In recent fiscal years, the Company has undertaken productivity improvement initiatives within all reportable segments at various locations across the U.S., Europe, and Japan. This includes workforce right-sizing and scalability initiatives, resulting in severance and transition costs; and cost related to the consolidation of facilities, resulting in asset impairment and accelerated depreciation charges. The Company’s existing lease obligations for certain facilities continue through various dates, the latest being 2028.

The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income.



	Three Months Ended
	March 30, 2019						March 31, 2018
	Severance and Transition Costs		Asset Impairments and Other Costs		Total		Severance and Transition Costs		Asset Impairments and Other Costs		Total
	(in thousands)
Cost of services provided and products sold (excluding amortization of intangible assets)	$	267	$	1,149	$	1,416	$	563	$	22	$	585
Selling, general and administrative	133		—		133		53		—		53
Total	$	400	$	1,149	$	1,549	$	616	$	22	$	638

The following table presents restructuring costs by reportable segment for these productivity improvement initiatives:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS	301		—
DSA	$	13	$	(232	)
Manufacturing	1,235		870
Total	$	1,549	$	638

2017 RMS Restructuring Initiative

In the fourth quarter of fiscal year 2017, the Company committed to a plan to further reduce costs and improve operating efficiencies in its RMS reportable segment. The plan included ceasing production within the Company’s facility in Maryland and reducing its workforce at certain RMS facilities during 2018.

The following table presents a summary of severance and transition costs, and asset impairments (referred to as restructuring costs) during the three months ended March 31, 2018 related to this initiative within the unaudited condensed consolidated statements of income. The Company did not incur any restructuring costs in the three months ended March 30, 2019.



	Three Months Ended
	March 31, 2018
	Severance and Transition Costs		Asset Impairments and Other Costs		Total

Cost of services provided and products sold (excluding amortization of intangible assets)	$	353	$	515	$	868
Selling, general and administrative	170		—		170
Total	$	523	$	515	$	1,038

Cumulative restructuring costs incurred during 2017 and 2018 were $20.1 million, which primarily related to non-cash asset impairments and accelerated depreciation charges of $17.7 million and cash payments for severance and transition costs of $1.2 million and were recorded in the RMS reportable segment. Substantially all severance and transition costs have been paid as of March 30, 2019 and no further restructuring costs related to the 2017 RMS Restructuring Initiative are expected to be incurred.

The following table provides a rollforward for all of the Company’s severance and transition costs, and lease obligation liabilities related to all restructuring activities:



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Beginning balance	$	2,921		$	6,856
Expense	1,246			1,139
Payments / utilization	(2,034		)	(1,149		)
Foreign currency adjustments	(20		)	207
Ending balance	$	2,113		$	7,053

As of March 30, 2019 and March 31, 2018, 1.8 million and $3.1 million of severance and other personnel related costs liabilities and lease obligation liabilities, respectively, were included in accrued compensation and accrued liabilities within the Company’s unaudited condensed consolidated balance sheets and $0.3 million and $3.9 million, respectively, were included in other long-term liabilities within the Company’s unaudited condensed consolidated balance sheets.

LEASES

3 Months Ended

Mar. 30, 2019

Leases [Abstract]

LEASES

Adoption of ASC Topic 842, “Leases” (ASC 842)

ASC 842 became effective for the Company on December 30, 2018 and was adopted using the modified retrospective method for all leases that had commenced as of the effective date, along with certain available practical expedients. The Company elected to recognize any effects of applying the new standard as a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption, which there were none. In addition, the Company elected to adopt the package of practical expedients permitted under the transition guidance within the new standard. The practical expedient package applied to leases that commenced prior to the effective date of the new standard and permits a reporting entity not to: i) reassess whether any expired or existing contracts are or contain leases, ii) reassess the historical lease classification for any expired or existing leases, and iii) reassess initial direct costs for any existing leases.

The reporting results for the three months ended March 30, 2019 reflect the application of ASC 842 guidance while the historical results for fiscal year 2018 were prepared under the guidance of ASC 840. The adoption of the new standard did not have a significant impact upon the Company’s condensed consolidated statements of income and cash flows. The adoption of the new standard resulted in the following impact to the condensed consolidated balance sheet: i) no significant change in the carrying values of assets and liabilities related to the Company’s finance leases, previously referred to as capital leases (See Note 9, “Long-Term Debt and Finance Lease Obligations”), ii) the derecognition of assets and related liabilities pertaining to certain build-to-suit arrangements previously accounted for under ASC 840 and recording them under the guidance of ASC 842, and iii) the recording of right-of-use assets and corresponding lease liabilities pertaining to the Company’s operating leases on the condensed consolidated balance sheet, adjusted for existing balances of prepaid rent and deferred rent liabilities as of the transition date. The cumulative effect of applying ASC 842 to all leases that had commenced as of December 30, 2018 was as follows:



Balance sheet captions impacted by ASC 842	December 30, 2018 (Prior to adoption of ASC 842)		Effect of the adoption of ASC 842				December 30, 2018 (As adjusted)
	(in thousands)
Prepaid assets	$	53,447	$	(4,413	)	⁽¹⁾	$	49,034
Property, plant and equipment, net	932,877		(23,448		)	⁽²⁾	909,429
Right-of-use asset-operating leases	—		134,172			⁽³⁾	134,172
Other assets	143,759		(4,989		)	⁽⁴⁾	138,770
Other current liabilities	71,280		15,935			⁽⁵⁾	87,215
Right-of-use liability-operating leases	—		111,570			⁽⁶⁾	111,570
Long-term debt, net and finance leases	1,636,598		(26,183		)	⁽⁷⁾	1,610,415
ASC 842 adoption adjustments:
⁽¹⁾ Short term prepaid rent reclassified from Prepaid assets to the Operating lease right-of-use asset.
⁽²⁾ Derecognition of approximately $26 million of leased properties, recorded in Property, plant and equipment, specifically Construction-in-process, that were recognized under the previously existing build-to-suit accounting rules; partially offset by Prepaid assets related to finance leases reclassified from Prepaid assets.
⁽³⁾ Recognition of Operating lease right-to-use asset and adjusted for prepaid rent and deferred rent liability reclassification adjustments identified in adjustments ⁽¹⁾ ⁽⁴⁾ ⁽⁵⁾.
⁽⁴⁾ Long-term prepaid rent reclassified from Other assets to the Operating lease right-of-use asset.
⁽⁵⁾ Recognition of short-term portion of the Operating lease right-of-use liabilities offset by reclassification of deferred rent liability to Operating lease right-of-use asset.
⁽⁶⁾ Recognition of long-term portion of the Operating lease right-of-use liabilities.
⁽⁷⁾ Derecognition of approximately $26 million of Other debt associated with leased properties that were recognized under the previously existing build-to-suit accounting rules.

Operating and Finance Leases

At inception of a contract, the Company determines if a contact meets the definition of a lease. A lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The Company determines if the contract conveys the right to control the use of an identified asset for a period of time. The Company assesses throughout the period of use whether the Company has both of the following: (1) the right to obtain substantially all of the economic benefits from use of the identified asset, and (2) the right to direct the use of the identified asset. This determination is reassessed if the terms of the contract are changed. Leases are classified as operating or finance leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future lease payments.

The Company leases laboratory, production, and office space (real estate), as well as land, vehicles and certain equipment under non-cancellable operating and finance leases. The carrying value of the Company’s right-of-use lease assets is substantially concentrated in its real estate leases, while the volume of lease agreements is primarily concentrated in vehicles and equipment leases. The Company’s policy is to not record leases with an original term of twelve months or less on the condensed consolidated balance sheets. The Company recognizes lease expense for these short-term leases on a straight-line basis over the lease term.

Certain lease agreements include rental payments that are adjusted periodically for inflation or other variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance and other expenses, which are generally referred to as non-lease components. Such adjustments to rental payments and variable non-lease components are treated as variable lease payments and recognized in the period in which the obligation for these payments was incurred. Variable lease components and variable non-lease components are not measured as part of the right of use asset and liability. Only when lease components and their associated non-lease components are fixed are they accounted for as a single lease component and are recognized as part of a right of use asset and liability. Total contract consideration is allocated to the combined fixed lease and non-lease component. This policy election applies consistently to all asset classes under lease agreements.

Most leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to purchase the leased property and options to terminate the lease. Payments to be made in option periods are recognized as part of the right-of-use lease assets and lease liabilities when it is reasonably certain that the option to extend the lease will be exercised or the option to terminate the lease will not be exercised, or is not at the Company’s option. The Company determines whether the reasonably certain threshold is met by considering contract-, asset-, market-, and entity-based factors.

A portfolio approach is applied to certain lease contracts with similar characteristics. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases.

The Company subleases a limited number of lease arrangements. Sublease activity is not material to the condensed consolidated financial statements.

Right-of-use lease assets and lease liabilities are reported in the Company’s condensed consolidated financial statements as follows:



	March 30, 2019
	(in thousands)
Operating leases
Right-of-use asset-operating leases	$	130,704

Other current liabilities	$	18,912
Right-of-use liability-operating leases	109,054
Total operating lease liabilities	$	127,966

Finance leases
Property, plant and equipment, net	$	30,774

Current portion of long-term debt and finance leases	$	2,430
Long-term debt, net and finance leases	26,509
Total finance lease liabilities	$	28,939

The components of operating and finance lease costs for the three months ended March 30, 2019 were as follows:



	March 30, 2019
	(in thousands)
Operating lease costs	$	7,706
Finance lease costs:
Amortization of right-of-use assets	921
Interest on lease liabilities	296
Short-term lease costs	192
Variable lease costs	335
Sublease income	(46		)
Total lease costs	$	9,404

Other information related to leases was as follows:

Supplemental cash flow information



	March 30, 2019
	(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	6,533
Operating cash flows from finance leases	352
Finance cash flows from finance leases	838

Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	—

Lease term and discount rate



		March 30, 2019
Weighted-average remaining lease term (in years)
Operating lease		7.71
Finance lease		14.19
Weighted-average discount rate
Operating lease		4.51
Finance lease		4.77

At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate.

As of March 30, 2019, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases		Finance Leases
	(in thousands)
2019 (excluding the three months ended March 30, 2019)	$	18,658	$	2,768
2020	22,915		3,797
2021	20,906		2,916
2022	17,595		3,034
2023	14,304		2,268
Thereafter	58,784		24,945
Total minimum future lease payments	153,162		39,728
Less: Imputed interest	25,196		10,789
Total lease liabilities	$	127,966	$	28,939

Total minimum future lease payments (predominantly operating leases) of approximately $27.9 million for leases that have not commenced as of March 30, 2019, as the Company does not yet control the underlying assets, are not included in the condensed consolidated financial statements. These leases are expected to commence between fiscal years 2019 and 2021 with lease terms of 3 to 11 years.

As of December 29, 2018, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases ⁽¹⁾		Finance Leases ⁽¹⁾
	(in thousands)
2019	$	25,411	$	3,972
2020	22,400		3,759
2021	21,544		2,869
2022	18,535		2,967
2023	15,398		2,209
Thereafter	66,870		24,304
Total minimum future lease payments	$	170,158	$	40,080
⁽¹⁾ Lease commitments are presented under the guidance of ASC 840 and includes approximately $14 million of minimum future lease payments for leases that had not commenced as of December 29, 2018. These commitments relate to existing leases for which the Company does not yet control certain expansion space.

LEASES

Adoption of ASC Topic 842, “Leases” (ASC 842)



Balance sheet captions impacted by ASC 842	December 30, 2018 (Prior to adoption of ASC 842)		Effect of the adoption of ASC 842				December 30, 2018 (As adjusted)
	(in thousands)
Prepaid assets	$	53,447	$	(4,413	)	⁽¹⁾	$	49,034
Property, plant and equipment, net	932,877		(23,448		)	⁽²⁾	909,429
Right-of-use asset-operating leases	—		134,172			⁽³⁾	134,172
Other assets	143,759		(4,989		)	⁽⁴⁾	138,770
Other current liabilities	71,280		15,935			⁽⁵⁾	87,215
Right-of-use liability-operating leases	—		111,570			⁽⁶⁾	111,570
Long-term debt, net and finance leases	1,636,598		(26,183		)	⁽⁷⁾	1,610,415
ASC 842 adoption adjustments:
⁽¹⁾ Short term prepaid rent reclassified from Prepaid assets to the Operating lease right-of-use asset.
⁽²⁾ Derecognition of approximately $26 million of leased properties, recorded in Property, plant and equipment, specifically Construction-in-process, that were recognized under the previously existing build-to-suit accounting rules; partially offset by Prepaid assets related to finance leases reclassified from Prepaid assets.
⁽³⁾ Recognition of Operating lease right-to-use asset and adjusted for prepaid rent and deferred rent liability reclassification adjustments identified in adjustments ⁽¹⁾ ⁽⁴⁾ ⁽⁵⁾.
⁽⁴⁾ Long-term prepaid rent reclassified from Other assets to the Operating lease right-of-use asset.
⁽⁵⁾ Recognition of short-term portion of the Operating lease right-of-use liabilities offset by reclassification of deferred rent liability to Operating lease right-of-use asset.
⁽⁶⁾ Recognition of long-term portion of the Operating lease right-of-use liabilities.
⁽⁷⁾ Derecognition of approximately $26 million of Other debt associated with leased properties that were recognized under the previously existing build-to-suit accounting rules.

Operating and Finance Leases

The Company subleases a limited number of lease arrangements. Sublease activity is not material to the condensed consolidated financial statements.

Right-of-use lease assets and lease liabilities are reported in the Company’s condensed consolidated financial statements as follows:



	March 30, 2019
	(in thousands)
Operating leases
Right-of-use asset-operating leases	$	130,704

Other current liabilities	$	18,912
Right-of-use liability-operating leases	109,054
Total operating lease liabilities	$	127,966

Finance leases
Property, plant and equipment, net	$	30,774

Current portion of long-term debt and finance leases	$	2,430
Long-term debt, net and finance leases	26,509
Total finance lease liabilities	$	28,939

The components of operating and finance lease costs for the three months ended March 30, 2019 were as follows:



	March 30, 2019
	(in thousands)
Operating lease costs	$	7,706
Finance lease costs:
Amortization of right-of-use assets	921
Interest on lease liabilities	296
Short-term lease costs	192
Variable lease costs	335
Sublease income	(46		)
Total lease costs	$	9,404

Other information related to leases was as follows:

Supplemental cash flow information



	March 30, 2019
	(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	6,533
Operating cash flows from finance leases	352
Finance cash flows from finance leases	838

Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	—

Lease term and discount rate



		March 30, 2019
Weighted-average remaining lease term (in years)
Operating lease		7.71
Finance lease		14.19
Weighted-average discount rate
Operating lease		4.51
Finance lease		4.77

As of March 30, 2019, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases		Finance Leases
	(in thousands)
2019 (excluding the three months ended March 30, 2019)	$	18,658	$	2,768
2020	22,915		3,797
2021	20,906		2,916
2022	17,595		3,034
2023	14,304		2,268
Thereafter	58,784		24,945
Total minimum future lease payments	153,162		39,728
Less: Imputed interest	25,196		10,789
Total lease liabilities	$	127,966	$	28,939

As of December 29, 2018, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases ⁽¹⁾		Finance Leases ⁽¹⁾
	(in thousands)
2019	$	25,411	$	3,972
2020	22,400		3,759
2021	21,544		2,869
2022	18,535		2,967
2023	15,398		2,209
Thereafter	66,870		24,304
Total minimum future lease payments	$	170,158	$	40,080
⁽¹⁾ Lease commitments are presented under the guidance of ASC 840 and includes approximately $14 million of minimum future lease payments for leases that had not commenced as of December 29, 2018. These commitments relate to existing leases for which the Company does not yet control certain expansion space.

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation Various lawsuits, claims and proceedings of a nature considered normal to its business are pending against the Company. While the outcome of any of these proceedings cannot be accurately predicted, the Company does not believe the ultimate resolution of any of these existing matters would have a material adverse effect on the Company’s business or financial condition.

BASIS OF PRESENTATION (Policies)	3 Months Ended
BASIS OF PRESENTATION (Policies)	Mar. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Consolidation	The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
Fiscal Period	The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31.
Newly Adopted and Newly Issued Accounting Pronouncements	In June 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-07, “Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” ASU 2018-07 aligns the accounting for share-based payment awards issued to employees and nonemployees as well as improves financial reporting for share-based payments to nonemployees. This standard became effective for the Company in the three months ended March 30, 2019 and did not have a material impact on the consolidated financial statements and related disclosures. In August 2017, the FASB issued ASU 2017-12, “Derivatives and Hedging (Topic 815) Targeted Improvements to Accounting for Hedging Activities.” ASU 2017-12 refines and expands hedge accounting for both financial and commodity risks. It also creates more transparency around how economic results are presented, both on the face of the financial statements and in the disclosures. In addition, this ASU makes certain targeted improvements to simplify the application of hedge accounting guidance. This standard became effective for the Company in the three months ended March 30, 2019 and did not have a material impact on the consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases.” The standard, including subsequently issued amendments, collectively referred to as Accounting Standards Codification (ASC) 842, “Leases”, established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The Company adopted this standard using the modified retrospective transition approach as applied to leases existing as of or entered into after the adoption date (December 30, 2018) in the three months ended March 30, 2019. See Note 16, “Leases” for a discussion of the Company’s adoption of this standard and its impact on the consolidated financial statements and related disclosures. Newly Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computer Arrangement that is a Service Contract.” ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years and will be applied either retrospectively or prospectively. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-14, “Compensation Retirement Benefits - Defined Benefit Plans -General (Subtopic 715-20).” ASU 2018-14 removes the requirements to disclose the amounts in Accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year and the related party disclosures about the amount of future annual benefits covered by insurance contracts. In addition, the ASU adds the requirement to disclose an explanation for any significant gains and losses related to changes in the benefit obligation for the period. The ASU is effective for fiscal years ending after December 15, 2020 and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 removes the disclosure requirement for the amount and reasons for transfers between Level 1 and Level 2 fair value measurements as well as the process for Level 3 fair value measurements. In addition, the ASU adds the disclosure requirements for changes in unrealized gains and losses included in Other comprehensive income (loss) for recurring Level 3 fair value measurements held at the end of the reporting period as well as the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. The ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years and will be applied on a retrospective basis to all periods presented. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” The standard simplifies the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. This standard is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019, and will be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses.” The standard requires a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and requires the modified retrospective approach. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its consolidated financial statements and related disclosures.

BUSINESS ACQUISITIONS (Tables)

3 Months Ended

Mar. 30, 2019

Business Combinations [Abstract]

Schedule of Purchase Price Allocation

The purchase price allocation of $21.5 million, net of $1.0 million of cash acquired and a final net working capital adjustment of $0.4 million, was as follows:



	January 11, 2018
	(in thousands)
Trade receivables (contractual amount of $1,309)	$	1,309
Other current assets (excluding cash)	99
Property, plant and equipment	1,136
Definite-lived intangible assets - client relationships	3,647
Goodwill	17,660
Current liabilities	(1,575		)
Deferred revenue	(151		)
Long-term liabilities	(596		)
Total purchase price allocation	$	21,529

The purchase allocation of $800.8 million, net of $27.7 million of cash acquired and a final net working capital adjustment of $1.2 million, was as follows:



	April 3, 2018
	(in thousands)
Trade receivables (contractual amount of $35,073)	$	35,073
Inventories	4,463
Other current assets (excluding cash)	5,893
Property, plant and equipment	128,403
Goodwill	441,656
Definite-lived intangible assets	309,200
Other long-term assets	1,081
Deferred revenue	(23,926		)
Current liabilities	(32,885		)
Deferred tax liabilities	(65,945		)
Other long-term liabilities	(2,213		)
Total purchase price allocation	$	800,800

Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination

The breakout of definite-lived intangible assets acquired was as follows:



	Definite-Lived Intangible Assets		Weighted Average Amortization Life
	(in thousands)		(in years)
Client relationships	$	264,900	13
Developed technology	23,400		3
Backlog	20,900		1
Total definite-lived intangible assets	$	309,200	12

Schedule of Business Acquisition, Pro Forma Information

For the three months ended March 31, 2018, these adjustments included additional amortization of intangible assets and depreciation of fixed assets of $6.9 million, additional interest expense on borrowings of $2.6 million, elimination of intercompany activity and other one-time costs, and the tax impacts of these adjustments.



	Three Months Ended
	March 31, 2018
	(in thousands)
Revenue	$	556,091
Net income attributable to common shareholders	49,414

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)

3 Months Ended

Mar. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Major Products/Service Lines:
RMS	$	137,172	$	133,958
DSA	354,197		259,992
Manufacturing	113,200		100,020
Total revenue	$	604,569	$	493,970



Timing of Revenue Recognition:
RMS
Services and products transferred over time	$	54,813	$	48,726
Services and products transferred at a point in time	82,359		85,232
DSA
Services and products transferred over time	354,078		259,744
Services and products transferred at a point in time	119		248
Manufacturing
Services and products transferred over time	31,896		28,571
Services and products transferred at a point in time	81,304		71,449
Total revenue	$	604,569	$	493,970

Revenue for each significant product or service offering is as follows:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS	$	137,172	$	133,958
DSA	354,197		259,992
Manufacturing	113,200		100,020
Total revenue	$	604,569	$	493,970

Revenue by geographic area is as follows:



	U.S.		Europe		Canada		Asia Pacific		Other		Consolidated
	(in thousands)
Three Months Ended:
March 30, 2019	$	350,176	$	166,365	$	53,979	$	33,179	$	870	$	604,569
March 31, 2018	248,980		160,826		48,578		34,520		1,066		493,970

Schedule of Estimated Revenue Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 30, 2019:



	Revenue Expected to be Recognized in Future Periods
	Less than 1 Year		1 to 3 Years		4 to 5 Years		Beyond 5 Years		Total
	(in thousands)
DSA	$	161,751	$	103,493	$	8,246	$	548	$	274,038
Manufacturing	7,158		20,363		1,706		81		29,308
Total	$	168,909	$	123,856	$	9,952	$	629	$	303,346

Schedule of Client Receivables, Contract Assets and Contract Liabilities

The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:



	March 30, 2019		December 29, 2018
	(in thousands)
Balances from contracts with customers:
Client receivables	$	377,188	$	370,131
Contract assets (unbilled revenue)	120,607		105,216
Contract liabilities (current and long-term deferred revenue)	166,705		179,559
Contract liabilities (customer contract deposits)	32,380		38,245

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 30, 2019

Segment Reporting [Abstract]

Schedule of Revenue and Other Financial Information by Business Segment

The following table presents revenue and other financial information by reportable segment:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS
Revenue	$	137,172	$	133,958
Operating income	37,832		38,527
Depreciation and amortization	4,322		4,853
Capital expenditures	4,112		4,625
DSA
Revenue	$	354,197	$	259,992
Operating income	46,705		40,859
Depreciation and amortization	33,784		20,787
Capital expenditures	8,848		12,802
Manufacturing
Revenue	$	113,200	$	100,020
Operating income	31,499		28,523
Depreciation and amortization	5,805		5,736
Capital expenditures	3,606		6,834

Reconciliation of Segment Operating Income to Consolidated Operating Income

The following table presents reconciliations of segment operating income, depreciation and amortization, and capital expenditures to the respective consolidated amounts:



	Operating Income						Depreciation and Amortization				Capital Expenditures
	March 30, 2019			March 31, 2018			March 30, 2019		March 31, 2018		March 30, 2019		March 31, 2018
	(in thousands)
Three Months Ended:
Total reportable segments	$	116,036		$	107,909		$	43,911	$	31,376	$	16,566	$	24,261
Unallocated corporate	(46,244		)	(40,080		)	1,447		1,834		165		3,465
Total consolidated	$	69,792		$	67,829		$	45,358	$	33,210	$	16,731	$	27,726

Revenue Disaggregated by Products and Services and Geographic Area

The following tables disaggregate the Company’s revenue by major business line and timing of transfer of products or services:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Major Products/Service Lines:
RMS	$	137,172	$	133,958
DSA	354,197		259,992
Manufacturing	113,200		100,020
Total revenue	$	604,569	$	493,970



Timing of Revenue Recognition:
RMS
Services and products transferred over time	$	54,813	$	48,726
Services and products transferred at a point in time	82,359		85,232
DSA
Services and products transferred over time	354,078		259,744
Services and products transferred at a point in time	119		248
Manufacturing
Services and products transferred over time	31,896		28,571
Services and products transferred at a point in time	81,304		71,449
Total revenue	$	604,569	$	493,970

Revenue for each significant product or service offering is as follows:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS	$	137,172	$	133,958
DSA	354,197		259,992
Manufacturing	113,200		100,020
Total revenue	$	604,569	$	493,970

Revenue by geographic area is as follows:



	U.S.		Europe		Canada		Asia Pacific		Other		Consolidated
	(in thousands)
Three Months Ended:
March 30, 2019	$	350,176	$	166,365	$	53,979	$	33,179	$	870	$	604,569
March 31, 2018	248,980		160,826		48,578		34,520		1,066		493,970

Summary of Unallocated Corporate Overhead

A summary of unallocated corporate expense consists of the following:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Stock-based compensation	$	8,274	$	6,991
Compensation, benefits, and other employee-related expenses	22,038		20,596
External consulting and other service expenses	3,810		2,934
Information technology	2,723		2,465
Depreciation	1,447		1,834
Acquisition and integration	5,472		2,864
Other general unallocated corporate	2,480		2,396
Total unallocated corporate expense	$	46,244	$	40,080

SUPPLEMENTAL BALANCE SHEET INFORMATION (Tables)

3 Months Ended

Mar. 30, 2019

Supplemental Balance Sheet Information [Abstract]

Composition of Net Trade Receivables

The composition of trade receivables, net is as follows:



	March 30, 2019			December 29, 2018
	(in thousands)
Client receivables	$	377,188		$	370,131
Unbilled revenue	120,607			105,216
Total	497,795			475,347
Less: Allowance for doubtful accounts	(2,294		)	(3,099		)
Trade receivables, net	$	495,501		$	472,248

Composition of Inventories

The composition of inventories is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Raw materials and supplies	$	22,118	$	22,378
Work in process	20,710		21,732
Finished products	86,937		83,782
Inventories	$	129,765	$	127,892

Composition of Other Current Assets

The composition of other current assets is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Prepaid income tax	$	54,153	$	47,157
Investments	907		885
Restricted cash	491		465
Other	500		300
Other current assets	$	56,051	$	48,807

Composition of Other Assets

The composition of other assets is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Venture capital investments	$	100,666	$	88,591
Life insurance policies	34,939		32,340
Restricted cash	1,499		1,411
Other	20,901		21,417
Other assets	$	158,005	$	143,759

Composition of Other Current Liabilities

The composition of other current liabilities is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
Current portion of right-of-use liabilities-operating leases	$	18,912	$	—
Accrued income taxes	25,725		24,120
Customer contract deposits	32,380		38,245
Other	14,455		8,915
Other current liabilities	$	91,472	$	71,280

Composition of Other Long-Term Liabilities

The composition of other long-term liabilities is as follows:



	March 30, 2019		December 29, 2018
	(in thousands)
U.S. Transition Tax	$	52,066	$	52,064
Long-term pension liability	24,589		24,671
Accrued executive supplemental life insurance retirement plan	36,522		36,086
Long-term deferred revenue	28,819		34,420
Other	31,566		31,880
Other long-term liabilities	$	173,562	$	179,121

FAIR VALUE (Tables)

3 Months Ended

Mar. 30, 2019

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis

Assets and liabilities measured at fair value on a recurring basis are summarized below:



	March 30, 2019
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	2,521	$	—	$	2,521
Other assets:
Life insurance policies	—		27,335		—		27,335
Total assets measured at fair value	$	—	$	29,856	$	—	$	29,856

Other current liabilities measured at fair value:
Contingent consideration	$	—	$	—	$	2,497	$	2,497



	December 29, 2018
	Level 1		Level 2		Level 3		Total
	(in thousands)
Cash equivalents	$	—	$	45,982	$	—	$	45,982
Other assets:
Life insurance policies	—		24,541		—		24,541
Total assets measured at fair value	$	—	$	70,523	$	—	$	70,523

Other current liabilities:
Contingent consideration	$	—	$	—	$	3,033	$	3,033
Foreign currency forward contract	—		1,319		—		1,319
Total liabilities measured at fair value	$	—	$	1,319	$	3,033	$	4,352

Rollforward of Contingent Consideration Related to Previous Acquisitions

The following table provides a rollforward of the contingent consideration related to previous business acquisitions. See Note 2, “Business Acquisitions.”



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Beginning balance	$	3,033		$	298
Additions	2,000			2,746
Payments	(2,610		)	—
Foreign currency translation	74			9
Ending balance	$	2,497		$	3,053

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Rollforward of Goodwill

The following table provides a rollforward of the Company’s goodwill:



			Adjustments to Goodwill
	December 29, 2018			Foreign Exchange			March 30, 2019
	(in thousands)
RMS	$	56,968		$	278		$	57,246
DSA	1,051,470			(2,341		)	1,049,129
Manufacturing	138,695			778			139,473
Goodwill	$	1,247,133		$	(1,285	)	$	1,245,848

Schedule of Intangible Assets

The following table displays intangible assets, net by major class:



	March 30, 2019							December 29, 2018
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
	(in thousands)
Backlog	$	20,900	$	(19,238	)	$	1,662	$	20,900	$	(18,691	)	$	2,209
Technology	102,038		(44,682		)	57,356		101,506		(41,870		)	59,636
Trademarks and trade names	8,411		(4,692		)	3,719		8,331		(4,640		)	3,691
Other	17,471		(10,557		)	6,914		17,448		(10,041		)	7,407
Other intangible assets	148,820		(79,169		)	69,651		148,185		(75,242		)	72,943
Client relationships	797,014		(271,906		)	525,108		791,725		(253,780		)	537,945
Intangible assets	$	945,834	$	(351,075	)	$	594,759	$	939,910	$	(329,022	)	$	610,888

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS (Tables)

3 Months Ended

Mar. 30, 2019

Debt Disclosure [Abstract]

Schedule of Debt

Long-term debt, net consists of the following:



	March 30, 2019			December 29, 2018
	(in thousands)
Term loans	$	721,875		$	731,250
Revolving facility	335,976			397,452
Senior Notes	500,000			500,000
Other debt	101			26,286
Finance leases	28,939			29,240
Total debt and finance leases	1,586,891			1,684,228
Less:
Current portion of long-term debt	28,225			28,228
Current portion of finance leases	2,430			3,188
Current portion of long-term debt and finance leases	30,655			31,416
Long-term debt and finance leases	1,556,236			1,652,812
Debt discount and debt issuance costs	(15,403		)	(16,214		)
Long-term debt, net and finance leases	$	1,540,833		$	1,636,598

EQUITY AND NONCONTROLLING INTEREST (Tables)

3 Months Ended

Mar. 30, 2019

Equity [Abstract]

Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Numerator:
Income from continuing operations, net of income taxes	$	55,688	$	53,268
Loss from discontinued operations, net of income taxes	—		(23		)
Less: Net income attributable to noncontrolling interests	555		614
Net income attributable to common shareholders	$	55,133	$	52,631

Denominator:
Weighted-average shares outstanding - Basic	48,458		47,785
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock	1,004		1,043
Weighted-average shares outstanding - Diluted	49,462		48,828

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:



	Foreign Currency Translation Adjustment and Other			Pension and Other Post-Retirement Benefit Plans			Total
	(in thousands)
December 29, 2018	$	(102,199	)	$	(70,504	)	$	(172,703	)
Other comprehensive income before reclassifications	9,427			—			9,427
Amounts reclassified from accumulated other comprehensive loss	—			374			374
Net current period other comprehensive income	9,427			374			9,801
Income tax (benefit) expense	(182		)	80			(102		)
March 30, 2019	$	(92,590	)	$	(70,210	)	$	(162,800	)

Rollforward Redeemable Noncontrolling Interest

The following table provides a rollforward of the activity related to the Company’s redeemable noncontrolling interest:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
Beginning balance	$	18,525	$	16,609
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest	85		150
Adjustment to redemption value	1,451		—
Foreign currency translation	458		564
Ending balance	$	20,519	$	17,323

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Tables)

3 Months Ended

Mar. 30, 2019

Retirement Benefits [Abstract]

Schedule of Net Periodic Cost

The following table provides the components of net periodic cost for the Company’s pension, deferred compensation and executive supplemental life insurance retirement plans:



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Service cost	$	630		$	846
Interest cost	2,875			2,833
Expected return on plan assets	(3,235		)	(3,877		)
Amortization of prior service cost (credit)	91			(181		)
Amortization of net loss	489			645
Net periodic cost	$	850		$	266

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 30, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation Expense

The following table provides stock-based compensation by the financial statement line item in which it is reflected:



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Cost of revenue	$	1,949		$	1,413
Selling, general and administrative	10,950			9,128
Stock-based compensation, before income taxes	12,899			10,541
Provision for income taxes	(2,047		)	(2,116		)
Stock-based compensation, net of income taxes	$	10,852		$	8,425

FOREIGN CURRENCY CONTRACT (Tables)

3 Months Ended

Mar. 30, 2019

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Notional and Fair Value of Foreign Currency Contracts

The notional amount and fair value of the open contract is summarized as follows:



	Notional Amount		Fair Value			Balance Sheet Location
	(in thousands)
December 29, 2018	$	343,300	$	(1,319	)	Other current liabilities

Schedule of Derivative Instruments on Statements of Income

The following table summarizes the effect of the foreign exchange forward contract on the Company’s unaudited condensed consolidated statements of income:



	Three Months Ended
	March 30, 2019					March 31, 2018
Location of hedge gain (loss)	Financial statement caption amount			Amount of gain (loss)		Financial statement caption amount			Amount of gain (loss)
	(in thousands)
Interest expense	$	(9,987	)	$	8,917	$	(11,191	)	$	—

RESTRUCTURING AND ASSET IMPAIRMENT (Tables)

3 Months Ended

Mar. 30, 2019

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Costs

The following table presents restructuring costs by reportable segment for these productivity improvement initiatives:



	Three Months Ended
	March 30, 2019		March 31, 2018
	(in thousands)
RMS	301		—
DSA	$	13	$	(232	)
Manufacturing	1,235		870
Total	$	1,549	$	638

The following table presents a summary of restructuring costs related to these initiatives within the unaudited condensed consolidated statements of income.



	Three Months Ended
	March 30, 2019						March 31, 2018
	Severance and Transition Costs		Asset Impairments and Other Costs		Total		Severance and Transition Costs		Asset Impairments and Other Costs		Total
	(in thousands)
Cost of services provided and products sold (excluding amortization of intangible assets)	$	267	$	1,149	$	1,416	$	563	$	22	$	585
Selling, general and administrative	133		—		133		53		—		53
Total	$	400	$	1,149	$	1,549	$	616	$	22	$	638

The Company did not incur any restructuring costs in the three months ended March 30, 2019.



	Three Months Ended
	March 31, 2018
	Severance and Transition Costs		Asset Impairments and Other Costs		Total

Cost of services provided and products sold (excluding amortization of intangible assets)	$	353	$	515	$	868
Selling, general and administrative	170		—		170
Total	$	523	$	515	$	1,038

Rollforward of Company's Severance and Transition Costs and Lease Obligation Liabilities

The following table provides a rollforward for all of the Company’s severance and transition costs, and lease obligation liabilities related to all restructuring activities:



	Three Months Ended
	March 30, 2019			March 31, 2018
	(in thousands)
Beginning balance	$	2,921		$	6,856
Expense	1,246			1,139
Payments / utilization	(2,034		)	(1,149		)
Foreign currency adjustments	(20		)	207
Ending balance	$	2,113		$	7,053

LEASES (Tables)

3 Months Ended

Mar. 30, 2019

Leases [Abstract]

Schedule of Cumulative Effect of Adoption of ASC 842

The cumulative effect of applying ASC 842 to all leases that had commenced as of December 30, 2018 was as follows:



Balance sheet captions impacted by ASC 842	December 30, 2018 (Prior to adoption of ASC 842)		Effect of the adoption of ASC 842				December 30, 2018 (As adjusted)
	(in thousands)
Prepaid assets	$	53,447	$	(4,413	)	⁽¹⁾	$	49,034
Property, plant and equipment, net	932,877		(23,448		)	⁽²⁾	909,429
Right-of-use asset-operating leases	—		134,172			⁽³⁾	134,172
Other assets	143,759		(4,989		)	⁽⁴⁾	138,770
Other current liabilities	71,280		15,935			⁽⁵⁾	87,215
Right-of-use liability-operating leases	—		111,570			⁽⁶⁾	111,570
Long-term debt, net and finance leases	1,636,598		(26,183		)	⁽⁷⁾	1,610,415
ASC 842 adoption adjustments:
⁽¹⁾ Short term prepaid rent reclassified from Prepaid assets to the Operating lease right-of-use asset.
⁽²⁾ Derecognition of approximately $26 million of leased properties, recorded in Property, plant and equipment, specifically Construction-in-process, that were recognized under the previously existing build-to-suit accounting rules; partially offset by Prepaid assets related to finance leases reclassified from Prepaid assets.
⁽³⁾ Recognition of Operating lease right-to-use asset and adjusted for prepaid rent and deferred rent liability reclassification adjustments identified in adjustments ⁽¹⁾ ⁽⁴⁾ ⁽⁵⁾.
⁽⁴⁾ Long-term prepaid rent reclassified from Other assets to the Operating lease right-of-use asset.
⁽⁵⁾ Recognition of short-term portion of the Operating lease right-of-use liabilities offset by reclassification of deferred rent liability to Operating lease right-of-use asset.
⁽⁶⁾ Recognition of long-term portion of the Operating lease right-of-use liabilities.
⁽⁷⁾ Derecognition of approximately $26 million of Other debt associated with leased properties that were recognized under the previously existing build-to-suit accounting rules.

Schedule of Right-of-Use Lease Assets and Lease Liabilities in Condensed Financial Statements

Right-of-use lease assets and lease liabilities are reported in the Company’s condensed consolidated financial statements as follows:



	March 30, 2019
	(in thousands)
Operating leases
Right-of-use asset-operating leases	$	130,704

Other current liabilities	$	18,912
Right-of-use liability-operating leases	109,054
Total operating lease liabilities	$	127,966

Finance leases
Property, plant and equipment, net	$	30,774

Current portion of long-term debt and finance leases	$	2,430
Long-term debt, net and finance leases	26,509
Total finance lease liabilities	$	28,939

Schedule of Operating and Finance Lease Costs and Supplemental Cash Flow Information

The components of operating and finance lease costs for the three months ended March 30, 2019 were as follows:



	March 30, 2019
	(in thousands)
Operating lease costs	$	7,706
Finance lease costs:
Amortization of right-of-use assets	921
Interest on lease liabilities	296
Short-term lease costs	192
Variable lease costs	335
Sublease income	(46		)
Total lease costs	$	9,404

Supplemental cash flow information



	March 30, 2019
	(in thousands)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	6,533
Operating cash flows from finance leases	352
Finance cash flows from finance leases	838

Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	—

Lease term and discount rate



		March 30, 2019
Weighted-average remaining lease term (in years)
Operating lease		7.71
Finance lease		14.19
Weighted-average discount rate
Operating lease		4.51
Finance lease		4.77

Schedule of Future Minimum Lease Payments Under Non-Cancellable Operating Leases After Adoption

As of March 30, 2019, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases		Finance Leases
	(in thousands)
2019 (excluding the three months ended March 30, 2019)	$	18,658	$	2,768
2020	22,915		3,797
2021	20,906		2,916
2022	17,595		3,034
2023	14,304		2,268
Thereafter	58,784		24,945
Total minimum future lease payments	153,162		39,728
Less: Imputed interest	25,196		10,789
Total lease liabilities	$	127,966	$	28,939

Schedule of Future Minimum Lease Payments Under Non-Cancellable Finance Leases After Adoption

As of March 30, 2019, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases		Finance Leases
	(in thousands)
2019 (excluding the three months ended March 30, 2019)	$	18,658	$	2,768
2020	22,915		3,797
2021	20,906		2,916
2022	17,595		3,034
2023	14,304		2,268
Thereafter	58,784		24,945
Total minimum future lease payments	153,162		39,728
Less: Imputed interest	25,196		10,789
Total lease liabilities	$	127,966	$	28,939

Schedule of Future Minimum Lease Payments, Non-Cancellable Operating Leases Before Adoption

As of December 29, 2018, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases ⁽¹⁾		Finance Leases ⁽¹⁾
	(in thousands)
2019	$	25,411	$	3,972
2020	22,400		3,759
2021	21,544		2,869
2022	18,535		2,967
2023	15,398		2,209
Thereafter	66,870		24,304
Total minimum future lease payments	$	170,158	$	40,080
⁽¹⁾ Lease commitments are presented under the guidance of ASC 840 and includes approximately $14 million of minimum future lease payments for leases that had not commenced as of December 29, 2018. These commitments relate to existing leases for which the Company does not yet control certain expansion space.

Schedule of Future Minimum Lease Payments, Non-Cancellable Capital Leases Before Adoption

As of December 29, 2018, minimum future lease payments under non-cancellable leases for each of the following five years and a total thereafter were as follows:



	Operating Leases ⁽¹⁾		Finance Leases ⁽¹⁾
	(in thousands)
2019	$	25,411	$	3,972
2020	22,400		3,759
2021	21,544		2,869
2022	18,535		2,967
2023	15,398		2,209
Thereafter	66,870		24,304
Total minimum future lease payments	$	170,158	$	40,080
⁽¹⁾ Lease commitments are presented under the guidance of ASC 840 and includes approximately $14 million of minimum future lease payments for leases that had not commenced as of December 29, 2018. These commitments relate to existing leases for which the Company does not yet control certain expansion space.

BUSINESS ACQUISITIONS - Narrative (Details) € in Millions, £ in Millions					3 Months Ended
	Apr. 29, 2019 EUR (€)	Apr. 29, 2019 USD ($)	Apr. 03, 2018 USD ($)	Jan. 11, 2018 USD ($)	Mar. 30, 2019 USD ($)	Mar. 30, 2019 GBP (£)	Mar. 31, 2018 USD ($)	Sep. 29, 2018 USD ($)	Sep. 29, 2018 GBP (£)	Mar. 26, 2018 USD ($)	Jan. 11, 2018 GBP (£)
Credit facility \| $2.3 Billion Credit Facility
Business Acquisition [Line Items]
Credit facility										$ 2,300,000,000.0
Citoxlab
Business Acquisition [Line Items]
Integration related costs and transaction costs					$ 5,200,000
MPI Research
Business Acquisition [Line Items]
Purchase price			$ 829,700,000
Integration related costs and transaction costs					100,000		$ 2,700,000
Purchase price allocation			800,800,000
Cash acquired			27,700,000
Adjustments related to prior period			1,200,000
Goodwill, amount expected to be deductible for tax purposes			$ 4,100,000
Weighted average amortization life of intangible assets acquired			12 years
MPI Research \| Client relationships
Business Acquisition [Line Items]
Weighted average amortization life of intangible assets acquired			13 years
KWS BioTest Limited
Business Acquisition [Line Items]
Purchase price				$ 20,300,000
Integration related costs and transaction costs					100,000		400,000
Purchase price allocation				21,529,000
Cash acquired				1,000,000
Adjustments related to prior period				$ 400,000
Undiscounted contingent payments								$ 2,600,000	£ 2.0		£ 3.0
Payments for contingent liabilities					$ 2,600,000	£ 2.0
KWS BioTest Limited \| Client relationships
Business Acquisition [Line Items]
Weighted average amortization life of intangible assets acquired					12 years	12 years
Depreciation and Amortization Expense \| MPI Research
Business Acquisition [Line Items]
Adjustments related to prior period							6,900,000
Interest expense \| MPI Research
Business Acquisition [Line Items]
Adjustments related to prior period							$ 2,600,000
Subsequent Event \| Citoxlab
Business Acquisition [Line Items]
Purchase price	€ 448	$ 500,000,000

BUSINESS ACQUISITIONS - MPI Research Purchase Price Allocation (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018	Apr. 03, 2018
Business Acquisition [Line Items]
Trade receivables, contractual amount			$ 35,073
Goodwill	$ 1,245,848	$ 1,247,133
MPI Research
Business Acquisition [Line Items]
Trade receivables			35,073
Inventories			4,463
Other current assets (excluding cash)			5,893
Property, plant and equipment			128,403
Goodwill			441,656
Definite-lived intangible assets			309,200
Other long-term assets			1,081
Deferred revenue			(23,926)
Current liabilities			(32,885)
Deferred tax liabilities			(65,945)
Other long-term liabilities			(2,213)
Total purchase price allocation			$ 800,800

BUSINESS ACQUISITIONS - MPI Research Definite-Lived Intangible Assets (Details) - MPI Research $ in Thousands	Apr. 03, 2018 USD ($)
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 309,200
Weighted Average Amortization Life	12 years
Client relationships
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 264,900
Weighted Average Amortization Life	13 years
Developed technology
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 23,400
Weighted Average Amortization Life	3 years
Backlog
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 20,900
Weighted Average Amortization Life	1 year

BUSINESS ACQUISITIONS - MPI Research Pro Forma Information (Details) - MPI Research $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($)
Business Acquisition [Line Items]
Revenue	$ 556,091
Net income attributable to common shareholders	$ 49,414

BUSINESS ACQUISITIONS - KWS BioTest Limited Purchase Price Allocation (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018	Apr. 03, 2018	Jan. 11, 2018
Business Acquisition [Line Items]
Trade receivables, contractual amount			$ 35,073
Goodwill	$ 1,245,848	$ 1,247,133
KWS BioTest Limited
Business Acquisition [Line Items]
Trade receivables, contractual amount				$ 1,309
Trade receivables				1,309
Other current assets (excluding cash)				99
Property, plant and equipment				1,136
Definite-lived intangible assets - client relationships				3,647
Goodwill				17,660
Current liabilities				(1,575)
Deferred revenue				(151)
Other long-term liabilities				(596)
Total purchase price allocation				$ 21,529

REVENUE FROM CONTRACTS WITH CUSTOMERS - Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Total revenue	$ 604,569	$ 493,970
RMS
Disaggregation of Revenue [Line Items]
Total revenue	137,172	133,958
RMS \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	54,813	48,726
RMS \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	82,359	85,232
DSA
Disaggregation of Revenue [Line Items]
Total revenue	354,197	259,992
DSA \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	354,078	259,744
DSA \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	119	248
Manufacturing
Disaggregation of Revenue [Line Items]
Total revenue	113,200	100,020
Manufacturing \| Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	31,896	28,571
Manufacturing \| Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	$ 81,304	$ 71,449

REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Dec. 29, 2018
Revenue from Contract with Customer [Abstract]
Payment terms	30 days
Unpaid advanced client billings	$ 12,000
Contract liabilities (customer contract deposits)	$ 32,380	$ 38,245
Percentage of unbilled revenue billed during period	70.00%
Percentage of contract liabilities recognized as revenue during period	60.00%

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Client receivables	$ 377,188	$ 370,131
Contract assets (unbilled revenue)	120,607	105,216
Contract liabilities (current and long-term deferred revenue)	166,705
Contract liabilities (customer contract deposits)	$ 32,380	38,245
Calculated under Revenue Guidance in Effect before Topic 606
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Client receivables		370,131
Contract assets (unbilled revenue)		105,216
Contract liabilities (current and long-term deferred revenue)		$ 179,559

SEGMENT INFORMATION - Narrative (Details)	3 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Mar. 30, 2019 segments
Segment Reporting [Abstract]
Number of reportable segments	3

SEGMENT INFORMATION - Revenue and Other Financial Information by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Total revenue	$ 604,569	$ 493,970
Operating income	69,792	67,829
Depreciation and amortization	45,358	33,210
Capital expenditures	16,731	27,726
RMS
Segment Reporting Information [Line Items]
Total revenue	137,172	133,958
Operating income	37,832	38,527
Depreciation and amortization	4,322	4,853
Capital expenditures	4,112	4,625
DSA
Segment Reporting Information [Line Items]
Total revenue	354,197	259,992
Operating income	46,705	40,859
Depreciation and amortization	33,784	20,787
Capital expenditures	8,848	12,802
Manufacturing
Segment Reporting Information [Line Items]
Total revenue	113,200	100,020
Operating income	31,499	28,523
Depreciation and amortization	5,805	5,736
Capital expenditures	$ 3,606	$ 6,834

SEGMENT INFORMATION - Reconciliation of Segment Operating Income, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Operating income	$ 69,792	$ 67,829
Depreciation and amortization	45,358	33,210
Capital expenditures	16,731	27,726
Total reportable segments
Segment Reporting Information [Line Items]
Operating income	116,036	107,909
Depreciation and amortization	43,911	31,376
Capital expenditures	16,566	24,261
Unallocated corporate
Segment Reporting Information [Line Items]
Operating income	(46,244)	(40,080)
Depreciation and amortization	1,447	1,834
Capital expenditures	$ 165	$ 3,465

SEGMENT INFORMATION - Revenue Per Significant Product or Service (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Total revenue	$ 604,569	$ 493,970
RMS
Segment Reporting Information [Line Items]
Total revenue	137,172	133,958
DSA
Segment Reporting Information [Line Items]
Total revenue	354,197	259,992
Manufacturing
Segment Reporting Information [Line Items]
Total revenue	$ 113,200	$ 100,020

SEGMENT INFORMATION - Summary of Unallocated Corporate Overhead (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Segment Reporting Information [Line Items]
Stock-based compensation	$ 12,899	$ 10,541
Unallocated corporate
Segment Reporting Information [Line Items]
Stock-based compensation	8,274	6,991
Compensation, benefits, and other employee-related expenses	22,038	20,596
External consulting and other service expenses	3,810	2,934
Information technology	2,723	2,465
Depreciation	1,447	1,834
Acquisition and integration	5,472	2,864
Other general unallocated corporate	2,480	2,396
Total unallocated corporate expense	$ 46,244	$ 40,080

SEGMENT INFORMATION - Disaggregation of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 604,569	$ 493,970
U.S.
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	350,176	248,980
Europe
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	166,365	160,826
Canada
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	53,979	48,578
Asia Pacific
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	33,179	34,520
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue	$ 870	$ 1,066

SUPPLEMENTAL BALANCE SHEET INFORMATION (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 30, 2018	Dec. 29, 2018	Mar. 31, 2018
Composition of trade receivables
Client receivables	$ 377,188		$ 370,131
Contract assets (unbilled revenue)	120,607		105,216
Total	497,795		475,347
Less: Allowance for doubtful accounts	(2,294)		(3,099)
Trade receivables, net	495,501		472,248
Composition of inventories
Raw materials and supplies	22,118		22,378
Work in process	20,710		21,732
Finished products	86,937		83,782
Inventories	129,765		127,892
Composition of other current assets
Prepaid income tax	54,153		47,157
Investments	907		885
Restricted cash	491		465	$ 605
Other	500		300
Other current assets	56,051		48,807
Composition of other assets
Venture capital investments	100,666		88,591
Life insurance policies	34,939		32,340
Restricted cash	1,499		1,411	$ 2,021
Other	20,901		21,417
Other assets	158,005	$ 138,770	143,759
Composition of other current liabilities
Current portion of right-of-use liabilities-operating leases	18,912
Accrued income taxes	25,725		24,120
Customer contract deposits	32,380		38,245
Other	14,455		8,915
Other current liabilities	91,472	$ 87,215	71,280
Composition of other long-term liabilities
U.S. Transition Tax	52,066		52,064
Long-term pension liability	24,589		24,671
Accrued executive supplemental life insurance retirement plan	36,522		36,086
Long-term deferred revenue	28,819		34,420
Other	31,566		31,880
Other long-term liabilities	$ 173,562		$ 179,121

VENTURE CAPITAL INVESTMENTS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Schedule of Equity Method Investments [Line Items]
Committed contribution	$ 124.4
Amount funded for venture capital investments	71.4
Dividends received	0.8	$ 7.1
Gains recognized from venture capital investments	$ 10.6	$ 6.5
Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	1.00%
Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	12.00%

FAIR VALUE - Narrative (Details) - Senior Notes - Senior Notes Due 2026 - USD ($) $ in Millions	Mar. 30, 2019	Dec. 29, 2018	Apr. 03, 2018
Debt Instrument [Line Items]
Stated interest rate			5.50%
Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500.0	$ 500.0
Estimated Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 520.0	$ 495.0

FAIR VALUE - Fair Value of Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 2,521	$ 45,982
Other assets:
Life insurance policies	27,335	24,541
Total assets measured at fair value	29,856	70,523
Other current liabilities measured at fair value:
Contingent consideration	2,497	3,033
Foreign currency forward contract		1,319
Total liabilities measured at fair value		4,352
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	0	0
Foreign currency forward contract		0
Total liabilities measured at fair value		0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,521	45,982
Other assets:
Life insurance policies	27,335	24,541
Total assets measured at fair value	29,856	70,523
Other current liabilities measured at fair value:
Contingent consideration	0	0
Foreign currency forward contract		1,319
Total liabilities measured at fair value		1,319
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Other assets:
Life insurance policies	0	0
Total assets measured at fair value	0	0
Other current liabilities measured at fair value:
Contingent consideration	$ 2,497	3,033
Foreign currency forward contract		0
Total liabilities measured at fair value		$ 3,033

FAIR VALUE - Contingent Consideration (Details) - Contingent Consideration - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 3,033	$ 298
Additions	2,000	2,746
Payments	(2,610)	0
Foreign currency translation	74	9
Ending balance	$ 2,497	$ 3,053

GOODWILL AND INTANGIBLE ASSETS - Rollforward of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 30, 2019 USD ($)
Changes in gross carrying amount and accumulated amortization of goodwill
December 29, 2018	$ 1,247,133
Foreign Exchange	(1,285)
March 30, 2019	1,245,848
RMS
Changes in gross carrying amount and accumulated amortization of goodwill
December 29, 2018	56,968
Foreign Exchange	278
March 30, 2019	57,246
DSA
Changes in gross carrying amount and accumulated amortization of goodwill
December 29, 2018	1,051,470
Foreign Exchange	(2,341)
March 30, 2019	1,049,129
Manufacturing
Changes in gross carrying amount and accumulated amortization of goodwill
December 29, 2018	138,695
Foreign Exchange	778
March 30, 2019	$ 139,473

GOODWILL AND INTANGIBLE ASSETS - Schedule of Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018
Other intangible assets
Gross	$ 945,834	$ 939,910
Accumulated Amortization	(351,075)	(329,022)
Net	594,759	610,888
Backlog
Other intangible assets
Gross	20,900	20,900
Accumulated Amortization	(19,238)	(18,691)
Net	1,662	2,209
Technology
Other intangible assets
Gross	102,038	101,506
Accumulated Amortization	(44,682)	(41,870)
Net	57,356	59,636
Trademarks and trade names
Other intangible assets
Gross	8,411	8,331
Accumulated Amortization	(4,692)	(4,640)
Net	3,719	3,691
Other
Other intangible assets
Gross	17,471	17,448
Accumulated Amortization	(10,557)	(10,041)
Net	6,914	7,407
Other intangible assets
Other intangible assets
Gross	148,820	148,185
Accumulated Amortization	(79,169)	(75,242)
Net	69,651	72,943
Client relationships
Other intangible assets
Gross	797,014	791,725
Accumulated Amortization	(271,906)	(253,780)
Net	$ 525,108	$ 537,945

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 30, 2018	Dec. 29, 2018
Debt Instrument [Line Items]
Finance leases	$ 28,939
Finance leases			$ 29,240
Total debt and finance leases	1,586,891		1,684,228
Current portion of long-term debt	28,225		28,228
Current portion of finance leases	2,430
Current portion of finance leases			3,188
Current portion of long-term debt and finance leases	30,655		31,416
Long-term debt and finance leases	1,556,236		1,652,812
Debt discount and debt issuance costs	(15,403)		(16,214)
Long-term debt, net and finance leases	1,540,833	$ 1,610,415	1,636,598
Term loans
Debt Instrument [Line Items]
Long-term debt, gross	721,875		731,250
Revolving facility
Debt Instrument [Line Items]
Long-term debt, gross	335,976		397,452
Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	500,000		500,000
Other debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 101		$ 26,286

LONG-TERM DEBT AND CAPITAL LEASE OBLIGATIONS - Narrative (Details) € in Millions					3 Months Ended
	Apr. 29, 2019 EUR (€)	Apr. 29, 2019 USD ($)	Apr. 03, 2018 USD ($)	Mar. 26, 2018 USD ($) payment	Mar. 30, 2019 USD ($)	Dec. 29, 2018 USD ($)	Feb. 12, 2018 USD ($)	Mar. 29, 2016 USD ($)
Debt Instrument [Line Items]
Weighted average interest rate					3.77%	4.24%
Number of consecutive fiscal quarters					1 year
Finance leases					$ 28,939,000
Finance leases						$ 29,240,000
Citoxlab \| Subsequent Event
Debt Instrument [Line Items]
Purchase price	€ 448	$ 500,000,000
Foreign Exchange Forward
Debt Instrument [Line Items]
Derivative amount					343,300,000
$1.65 Billion Credit Facility \| Credit facility
Debt Instrument [Line Items]
Credit facility								$ 1,650,000,000.00
$2.3 Billion Credit Facility \| Credit facility
Debt Instrument [Line Items]
Credit facility				$ 2,300,000,000.0
Gross debt issuance costs					6,200,000
Debt issuance costs					1,000,000
Maximum borrowing capacity, term loan and line of credit facility, potential increase available				$ 1,000,000,000.0
Minimum EBITDA less capital expenditures to consolidated cash interest expense ratio				3.50
Maximum consolidated indebtedness to consolidated EBITDA				4.50
Maximum consolidated indebtedness to consolidated EBITDA, with step-downs				3.50
$2.3 Billion Credit Facility \| Credit facility \| Federal Funds Rate
Debt Instrument [Line Items]
Interest rate				0.50%
$2.3 Billion Credit Facility \| Credit facility \| LIBOR
Debt Instrument [Line Items]
Interest rate				1.00%
$2.3 Billion Credit Facility \| Credit facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility				$ 1,550,000,000.00
Term Loan \| Credit facility
Debt Instrument [Line Items]
Credit facility				$ 750,000,000.0
Number of quarterly installment payments \| payment				19
Senior Notes Due 2026 \| Senior Notes
Debt Instrument [Line Items]
Gross debt issuance costs			$ 7,400,000
Aggregate principal amount			$ 500,000,000
Stated interest rate			5.50%
Redemption price percentage, conditional upon equity offerings			40.00%
Redemption price percentage in the event of a change of control			101.00%
Net proceeds from debt			$ 493,800,000
Senior Notes Due 2026 \| Senior Notes \| Redemption Period One
Debt Instrument [Line Items]
Redemption price percentage			100.00%
Senior Notes Due 2026 \| Senior Notes \| Redemption Period Two
Debt Instrument [Line Items]
Redemption price percentage			105.50%
Bridge Loan
Debt Instrument [Line Items]
Credit facility							$ 830,000,000
Gross debt issuance costs					1,800,000
Fees paid for temporary backstop facility					2,000,000
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding					$ 6,500,000	$ 6,500,000

EQUITY AND NONCONTROLLING INTEREST - Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Numerator:
Income from continuing operations, net of income taxes	$ 55,688	$ 53,268
Loss from discontinued operations, net of income taxes	0	(23)
Less: Net income attributable to noncontrolling interests	555	614
Net income attributable to common shareholders	$ 55,133	$ 52,631
Denominator:
Weighted-average shares outstanding—Basic (in shares)	48,458	47,785
Effect of dilutive securities:
Stock options, restricted stock units, performance share units and restricted stock (in shares)	1,004	1,043
Weighted-average shares outstanding—Diluted (in shares)	49,462	48,828

EQUITY AND NONCONTROLLING INTEREST - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Contractually defined redemption value	$ 20.5
Vital River
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Noncontrolling interest ownership percentage	13.00%
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	0.4	0.5
Restricted Stock and Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount (in shares)	1.0	1.1

EQUITY AND NONCONTROLLING INTEREST - Treasury Shares (Details) - USD ($)	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Treasury Shares
Purchase of treasury stock	$ 17,760,000	$ 13,549,000
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)	100,000	100,000
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments	$ 17,800,000	$ 13,500,000
Authorized Share Repurchase Program
Treasury Shares
Purchase of treasury stock	$ 0	$ 0
Stock repurchased during period (in shares)	0	0
Remaining authorized repurchase amount	$ 129,100,000

EQUITY AND NONCONTROLLING INTEREST - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	$ 1,319,778	$ 1,047,407
Other comprehensive income before reclassifications	9,427
Amounts reclassified from accumulated other comprehensive loss	374
Net current period other comprehensive income	9,801
Income tax (benefit) expense	(102)	1,722
Ending balance	1,401,029	1,142,617
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(102,199)
Other comprehensive income before reclassifications	9,427
Amounts reclassified from accumulated other comprehensive loss	0
Net current period other comprehensive income	9,427
Income tax (benefit) expense	(182)
Ending balance	(92,590)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(70,504)
Other comprehensive income before reclassifications	0
Amounts reclassified from accumulated other comprehensive loss	374
Net current period other comprehensive income	374
Income tax (benefit) expense	80
Ending balance	(70,210)
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(172,703)	(144,731)
Ending balance	$ (162,800)	$ (124,457)

EQUITY AND NONCONTROLLING INTEREST - Rollforward of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 18,525	$ 16,609
Total gains or losses (realized/unrealized):
Adjustment to redemption value	1,451	0
Foreign currency translation	458	564
Ending balance	20,519	17,323
Net income attributable to noncontrolling interest
Total gains or losses (realized/unrealized):
Net income attributable to noncontrolling interest	$ 85	$ 150

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Mar. 30, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Effective tax rate	16.00%	15.50%
Increase in unrecognized tax benefits	$ 0.7
Unrecognized tax benefits	19.5
Increase in unrecognized tax benefits that would impact effective tax rate	0.5
Unrecognized tax benefits that would impact effective tax rate	18.1
Accrued interest and penalties on unrecognized tax benefits	2.9
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period (up to)	$ 8.2

PENSION AND OTHER POST-RETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Pension
Employee benefits
Service cost	$ 630	$ 846
Interest cost	2,875	2,833
Expected return on plan assets	(3,235)	(3,877)
Amortization of prior service cost (credit)	91	(181)
Amortization of net loss	489	645
Net periodic cost	850	266
Other Postretirement Benefits Plan
Employee benefits
Net periodic cost	$ 0	$ 0

STOCK-BASED COMPENSATION - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 12,899	$ 10,541
Provision for income taxes	(2,047)	(2,116)
Stock-based compensation, net of income taxes	10,852	8,425
Cost of revenue
Stock-based compensation expense
Stock-based compensation, before income taxes	1,949	1,413
Selling, general and administrative
Stock-based compensation expense
Stock-based compensation, before income taxes	$ 10,950	$ 9,128

STOCK-BASED COMPENSATION - Summary of Stock-Based Compensation Grants (Details) shares in Millions	3 Months Ended
	Mar. 30, 2019 $ / shares shares
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)	0.4
Stock options weighted average grant date fair value (in dollars per share) \| $ / shares	$ 34.00
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 144.35
Performance Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.2
Weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 162.74
Maximum shares to be awarded under plan (in shares)	0.3

FOREIGN CURRENCY CONTRACT - Narrative (Details)	Mar. 26, 2018 USD ($)
Credit facility \| $2.3 Billion Credit Facility
Derivative [Line Items]
Credit facility	$ 2,300,000,000.0

FOREIGN CURRENCY CONTRACT - Schedule of Notional and Fair Value of Foreign Currency Contracts (Details) - Foreign Exchange Forward - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 29, 2018
Derivatives, Fair Value [Line Items]
Notional Amount	$ 343,300
Not Designated as Hedging Instrument \| Other Current Assets
Derivatives, Fair Value [Line Items]
Notional Amount		$ 343,300
Fair Value		$ (1,319)

FOREIGN CURRENCY CONTRACT - Schedule of Derivative Instruments on Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Interest expense	$ (9,987)	$ (11,191)
Foreign Exchange Forward \| Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss)	$ 8,917	$ 0

RESTRUCTURING AND ASSET IMPAIRMENT - Restructuring Costs by Classification on the Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,549	$ 638
Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,416	585
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	133	53
Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	400	616
Severance and Transition Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	267	563
Severance and Transition Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	133	53
Asset Impairments and Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,149	22
Asset Impairments and Other Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,149	22
Asset Impairments and Other Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 0	$ 0

RESTRUCTURING AND ASSET IMPAIRMENT - Restructuring Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		24 Months Ended
	Mar. 30, 2019	Mar. 31, 2018	Dec. 29, 2018
Segment Reporting Information [Line Items]
Restructuring costs	$ 1,549	$ 638
RMS
Segment Reporting Information [Line Items]
Restructuring costs	301	0	$ 20,100
DSA
Segment Reporting Information [Line Items]
Restructuring costs	13	(232)
Manufacturing
Segment Reporting Information [Line Items]
Restructuring costs	$ 1,235	$ 870

RESTRUCTURING AND ASSET IMPAIRMENT - Restructuring Costs by Related to RMS Restructuring Initiative (Details) - USD ($)	3 Months Ended		24 Months Ended
	Mar. 30, 2019	Mar. 31, 2018	Dec. 29, 2018
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	$ 1,549,000	$ 638,000
Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	1,416,000	585,000
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	133,000	53,000
Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	400,000	616,000
Severance and Transition Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	267,000	563,000
Severance and Transition Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	133,000	53,000
Asset Impairments and Other Costs
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	1,149,000	22,000
Asset Impairments and Other Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	1,149,000	22,000
Asset Impairments and Other Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	0	0
RMS
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	301,000	0	$ 20,100,000
RMS \| Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs			$ 1,200,000
2017 RMS Restructuring \| RMS
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs	$ 0	1,038,000
2017 RMS Restructuring \| RMS \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		868,000
2017 RMS Restructuring \| RMS \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		170,000
2017 RMS Restructuring \| RMS \| Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		523,000
2017 RMS Restructuring \| RMS \| Severance and Transition Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		353,000
2017 RMS Restructuring \| RMS \| Severance and Transition Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		170,000
2017 RMS Restructuring \| RMS \| Asset Impairments and Other Costs
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		515,000
2017 RMS Restructuring \| RMS \| Asset Impairments and Other Costs \| Cost of services provided and products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		515,000
2017 RMS Restructuring \| RMS \| Asset Impairments and Other Costs \| Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Total severance and transition costs		$ 0

RESTRUCTURING AND ASSET IMPAIRMENT - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		24 Months Ended
	Mar. 30, 2019	Mar. 31, 2018	Dec. 29, 2018	Dec. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,549	$ 638
Severance and other personnel related costs liability and lease obligation liabilities	2,113	7,053	$ 2,921	$ 6,856
Accrued Compensation
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	1,800	3,100
RMS
Restructuring Cost and Reserve [Line Items]
Restructuring costs	301	0	20,100
Asset Impairments and Accelerated Depreciation \| RMS
Restructuring Cost and Reserve [Line Items]
Restructuring costs			17,700
Severance and Transition Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	400	616
Severance and Transition Costs \| Other Noncurrent Liabilities
Restructuring Cost and Reserve [Line Items]
Severance and other personnel related costs liability and lease obligation liabilities	$ 300	$ 3,900
Severance and Transition Costs \| RMS
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 1,200

RESTRUCTURING AND ASSET IMPAIRMENT - Rollforward of Severance and Transition Costs Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2019	Mar. 31, 2018
Restructuring Reserve [Roll Forward]
Beginning balance	$ 2,921	$ 6,856
Expense	1,246	1,139
Payments / utilization	(2,034)	(1,149)
Foreign currency adjustments	(20)	207
Ending balance	$ 2,113	$ 7,053

LEASES - Schedule of Cumulative Effect of Adoption of ASC 842 (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 30, 2018	Dec. 29, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid assets	$ 58,549	$ 49,034	$ 53,447
Property, plant and equipment, net	907,367	909,429	932,877
Right-of-use asset-operating leases	130,704	134,172
Other assets	158,005	138,770	143,759
Other current liabilities	91,472	87,215	71,280
Right-of-use liability-operating leases	109,054	111,570
Long-term debt, net and finance leases	$ 1,540,833	1,610,415	$ 1,636,598
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid assets		(4,413)
Property, plant and equipment, net		(23,448)
Right-of-use asset-operating leases		134,172
Other assets		(4,989)
Other current liabilities		15,935
Right-of-use liability-operating leases		111,570
Long-term debt, net and finance leases		$ (26,183)

LEASES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 30, 2018	Dec. 29, 2018
Lessor, Lease, Description [Line Items]
Derecognition of leased properties recorded in property, plant and equipment	$ (907,367)	$ (909,429)	$ (932,877)
Derecognition of other debt associated with leased properties	(1,540,833)	(1,610,415)	$ (1,636,598)
Future minimum lease payments for leases that have not yet commenced	$ 27,900
Minimum
Lessor, Lease, Description [Line Items]
Operating lease renewal term	1 year
Terms for leases that have not yet commenced	3 years
Maximum
Lessor, Lease, Description [Line Items]
Operating lease renewal term	5 years
Terms for leases that have not yet commenced	11 years
Accounting Standards Update 2016-02
Lessor, Lease, Description [Line Items]
Derecognition of leased properties recorded in property, plant and equipment		23,448
Derecognition of other debt associated with leased properties		26,183
Build-To-Suit Lease \| Accounting Standards Update 2016-02
Lessor, Lease, Description [Line Items]
Derecognition of leased properties recorded in property, plant and equipment		26,000
Derecognition of other debt associated with leased properties		$ 26,000

LEASES - Right-of-Use Lease Assets and Lease Liabilities in Condensed Consolidated Financial Statements (Details) - USD ($) $ in Thousands	Mar. 30, 2019	Dec. 30, 2018
Leases [Abstract]
Right-of-use asset-operating leases	$ 130,704	$ 134,172
Other current liabilities	18,912
Right-of-use liability-operating leases	109,054	$ 111,570
Total operating lease liabilities	127,966
Finance leases - property, plant and equipment, net	30,774
Current portion of long-term debt and finance leases	2,430
Long-term debt, net and finance leases	26,509
Total finance lease liabilities	$ 28,939

LEASES - Components of Operating and Finance Lease Costs (Details) $ in Millions	3 Months Ended
	Mar. 30, 2019 USD ($)
Leases [Abstract]
Operating lease costs	$ 7,706
Amortization of right-of-use assets	921
Interest on lease liabilities	296
Short-term lease costs	192
Variable lease costs	335
Sublease income	(46)
Total lease costs	$ 9,404

LEASES - Supplemental Cash Flow Information (Details) $ in Millions	3 Months Ended
	Mar. 30, 2019 USD ($)
Cash flows included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 6,533
Operating cash flows from finance leases	352
Finance cash flows from finance leases	838
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	1,688
Right-of-use lease assets obtained in exchange for new finance lease liabilities	$ 0

LEASES - Weighted Average Remaining Lease Term and Discount Rates (Details)	Mar. 30, 2019
Weighted-average remaining lease term (in years)
Operating lease	7 years 8 months 15 days
Finance lease	14 years 2 months 8 days
Weighted-average discount rate
Operating lease	4.51%
Finance lease	4.77%

LEASES - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases After Adoption (Details) $ in Thousands	Mar. 30, 2019 USD ($)
Operating Leases, After Adoption of 842
2019 (excluding the three months ended March 30, 2019)	$ 18,658
2020	22,915
2021	20,906
2022	17,595
2023	14,304
Thereafter	58,784
Total minimum future lease payments	153,162
Less: Imputed interest	25,196
Total lease liabilities	127,966
Finance Leases, After Adoption of 842
2019 (excluding the three months ended March 30, 2019)	2,768
2020	3,797
2021	2,916
2022	3,034
2023	2,268
Thereafter	24,945
Total minimum future lease payments	39,728
Less: Imputed interest	10,789
Total lease liabilities	$ 28,939

LEASES - Schedule of Future Minimum Lease Payments, Non-Cancellable Operating Leases Before Adoption (Details) $ in Thousands	Dec. 29, 2018 USD ($)
Operating Leases, Before Adoption of 842
2019	$ 25,411
2020	22,400
2021	21,544
2022	18,535
2023	15,398
Thereafter	66,870
Total minimum future lease payments	170,158
Capital Leases, Before Adoption of 842
2019	3,972
2020	3,759
2021	2,869
2022	2,967
2023	2,209
Thereafter	24,304
Total minimum future lease payments	40,080
Minimum future lease payments for leases that have not yet commenced	$ 14,000

Label	Element	Value
Accounting Standards Update 2016-01 [Member] \| Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,425,000
Accounting Standards Update 2016-01 [Member] \| Total Equity Attributable to Common Shareholders [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,425,000

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Estimated Revenue Related to Performance Obligations (Details) $ in Thousands	Mar. 30, 2019 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-03-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 168,909
Performance obligations expected to be satisfied, expected timing	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 123,856
Performance obligations expected to be satisfied, expected timing	2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 9,952
Performance obligations expected to be satisfied, expected timing	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 629
Performance obligations expected to be satisfied, expected timing
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 303,346
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-03-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	161,751
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	103,493
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	8,246
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	548
DSA \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	274,038
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-03-31
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	7,158
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	20,363
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	1,706
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	81
Manufacturing \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations expected to be satisfied	$ 29,308